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Summary
 
The purpose of this study was to explore multiple symptoms in lung cancer patients 
before and after surgery and to identify predictors of patients’ symptom burden 
(including age). In total, 264 lung cancer patients were recruited from 3 university 
hospitals. They completed questionnaires preoperatively, and 1 and 5 months after 
surgery. 
The study revealed that patients’ experienced a mean of 10 symptoms before 
surgery, with only small differences in the older patients compared to the younger 
ones (>65 years). When comparing the occurrence of symptoms before and after 
surgery, there was a significant increase in the mean number of symptoms at 1 
month. However, the only characteristic that was associated with a higher number of 
symptoms 1 month after surgery was the number of symptoms reported before 
surgery. At 5 months, the number of symptoms was reduced compared to the 1 
month assessment, but it was still significantly higher compared to the preoperative 
assessment. A total of 79% of the patients experienced shortness of breath (SOB) 5 
months after surgery, while 71% experienced lack of energy, and 56% reported pain. 
Some of the symptoms were intense. Our findings show that patients with more 
comorbidities and a higher number of preoperative symptoms need special attention, 
as they tend to experience a higher number of postoperative symptoms. Even though 
it is recommended in guidelines, only 32% of the patients had physical therapy after 
surgery and 16% had inpatient rehabilitation. While 30% of the patients were working 
preoperatively, only 9% worked at 5 months.  
This study provides important information about the symptom burden of 
patients that underwent lung cancer surgery, and about the most vulnerable patients. 
The results can be used to educate patients about the normal course of 
postoperative recovery. Clinicians need to perform a comprehensive symptom 
assessment prior to surgery and at regular intervals after surgery.  
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1.0INTRODUCTION
 Lung cancer is an important cause of morbidity and mortality across the 
world. It is a leading cause of cancer deaths (1, 2). Surgical resection is considered 
the treatment of choice for patients with early stage, non-small cell lung cancer (2). 
Lung cancer patients are normally diagnosed shortly before surgery and the 
operation is extensive. After 7 to 10 days, patients are discharged to their homes. 
Transitioning from one care setting to another is a risky part of patient care (3, 4). 
The transfer increases the risk for medications errors, discontinuity in patients’ follow-
up visits, and worsening of symptoms (5-7).  
Both preoperatively and before discharge from the hospital, patients want 
information about the usual course of recovery of their physical and mental health (8, 
9). However, limited information is available on lung cancer patients’ specific 
preferences following surgical treatment. In one study that presented hypothetical 
scenarios to 64 patients to assess their preferences for information following lung 
surgery (8), patients wanted information about postoperative outcomes (e.g., need 
for nursing home placement, oxygen dependence, restrictions in mobility, limitations 
in activities of daily living) before surgery to help them decide whether or not they 
want to have the surgery (8).  
At hospital discharge, patients need information about common symptoms and 
when to seek care for unrelieved symptoms (9). Patients often experience several 
symptoms simultaneously. The co-occurrence of multiple symptoms is reported to be 
associated with significant decreases in functional status and quality of life (QOL) 
(10). In addition to the occurrence of the symptom, its frequency, severity, and 
associated distress are described to influence the patient’s symptom experience (11). 
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Therefore, it is assumed to be of importance to assess more than the occurrence of 
the symptom to capture the symptom experience.   
The idea and inspiration for the study came from results of a previous study at 
Oslo University Hospital (OUH). In that study, data were collected using semi-
structured qualitative interviews with 11 patients, 3 months after lung cancer surgery 
(12). The patients described a postoperative period characterized by discomfort and 
lack of support from clinicians. They expressed a need for information about the 
normal postoperative period and when to contact a clinician (12). However, there is 
limited research about these patients rehabilitation phase.  
At the initiation of this dissertations research, a literature review was done. 
The literature search focused on patients who underwent surgery for lung cancer, 
because patients who are not offered surgery are described to experience different 
symptoms (13-15). A significant gap in the literature on patients’ symptoms and 
predictors of symptoms before and after lung cancer surgery was identified. Only four 
studies had evaluated symptoms in lung cancer patients prior to and after surgery 
(14, 16-18). In addition, only one study evaluated the severity and predictors of six 
symptoms at 1 and 4 months after lung cancer surgery (19).  
Although the previous studies provided interesting information, several 
limitations were noted. First, these studies evaluated a limited number of symptoms 
(14, 16-19) , mainly because their main focus was to assess QOL (16-18). In 
addition, these evaluations were limited to either ratings of symptom severity (16-19) 
or symptom distress (14). Only two of the previous studies reported predictors of 
patients’ symptom burden (14, 19). Assessment of predictors of patients’ symptom 
burden is important for identifying vulnerable groups of patients. The literature review 
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revealed a need for a more comprehensive study that assed multiple symptoms and 
predictors of these symptoms; evaluated multiple dimensions of symptoms (i.e., 
occurrence of, frequency, severity, distress), in a larger sample patients, from prior to 
and following lung cancer surgery.  
Lung cancer is a disease of the elderly (20). Older lung cancer patients have a 
higher number of comorbid conditions (21) and a higher number of comorbid 
conditions is associated with that patients report an increase the number of 
symptoms (14, 18). This study was conducted to gain knowledge about the symptom 
burden of elderly lung cancer patients from before through 5 months after surgery. 
Based on previous studies (15, 22, 23)SDWLHQWVLQWKLVVWXG\ZKRZHUH\HDUVRI
age were categorized as older. Due to the limited information about symptoms in 
lung cancer patients who undergo surgery and for comparative purposes, both older 
and younger patients were included in this study. Since in the first paper, few 
differences were found in the majority of symptoms between the two age groups; age 
was not the main theme in the other two papers.  
The Theory of Symptom Management (TSM) was chosen as the theoretical 
framework for this study, because it can be used as a guide to understand the 
patient’s symptom experience, particularly in terms of the multiple dimensions of 
symptoms (10). The three essential dimensions of the TSM are symptom experience, 
symptom management strategies, and symptom status outcomes. Due to the lack of 
evidence about surgically treated lung cancer patients’ symptoms, the main focus of 
the study was on patients’ symptom experience. Symptom experience is defined as a 
simultaneous perception, evaluation, and response to a change in one’s usual feeling 
(10). Knowledge about a patient’s symptom experience is necessary to develop and 
14 
 
test interventions to improve patients’ symptom management (10, 24, 25) and to 
change patients’ symptom status outcomes.  
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2.0 BACKGROUND
2.1 Lung cancer 
More than 600.000 patients are diagnosed with lung cancer in the United States and 
Europe annually (26, 27). In Norway, at the time of this study in 2011, 2842 patients 
were diagnosed with lung cancer and 57% of them were men and 43% women (28). 
As the incidence of lung cancer increases, especially in women, the social and 
economic burden of this disease increases as well (29, 30). Factors like occupational 
and environmental exposures and genetic characteristics are risk factors for the 
development of lung cancer (31, 32). However, smoking is the main cause of lung 
cancer. Approximately 10% to 20% of smokers develop lung cancer (32). The 
duration of smoking, the number of cigarettes smoked per day, and the age when 
smoking was initiated are some of the determinants associated with this risk factor. 
Lung cancer is difficult to detect because in the early stages of the disease 
patients are often asymptomatic (32). As a result, patients diagnosed with lung 
cancer often have regional or distant spread at the time of diagnosis. Cancer 
statistics from the United States report that only 15.3% of lung cancer patients are 
diagnosed with localized disease (i.e., cancer found only in the part of the body 
where it started) (33). 
Lung cancer is broadly categorized into small cell lung cancer (SCLC) and 
non–small cell cancer (NSCLC), based on histological differences in the tumor cells. 
NSCLC accounts for 80% of the cases while SCLC makes up 20% (31). NSCLC is 
further divided into three major and several minor histologic classes. The major 
histologic classes are adenocarcinoma, squamous cell carcinoma, and large cell 
carcinoma (34). NSCLC is staged based on the TNM system (i.e., tumor (T), node 
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(N), and metastasis (M)). SCLC  is not TNM staged but divided into limited or 
extensive disease (35). 
The TNM classification system is used to stage the extent of NSCLC lung 
cancer. The T category describes the size and extent of the primary tumor; the N 
category describes the extent of involvement of regional lymph nodes; while the M 
category describes the presence or absence of distant metastasis (36). The TNM 
classification provides an indication of prognosis and aids clinicians in treatment 
planning (31). Based on the combinations of TNM staging, NSCLC is divided into 
stages from 0 – IV (i.e. Stage 0, Stage IA, Stage IB, Stage IIA, Stage IIB, Stage IIIA, 
Stage IIIB, Stage IV). While the staging system was revised in 2010, Stage 0 
indicates no evidence of primary tumor and Stage IV indicates the presence of 
metastatic spread (31). 
Lung cancer is the most frequent cause of cancer deaths in Europe (26). In 
Norway in 2011, the 5 year survival rates for lung cancer patients were 12.1% for 
men and 16.8% for women (28). The survival rates for patients with early stage lung 
cancer (both NSCLC and SCLC) have improved over the past 25 years, due to 
improved surgical procedures, better patient selection and follow-up, and the use of 
adjuvant chemotherapy (CTX) (37-39).  
The 5 year survival rates for NSCLC depend on both the time of diagnose 
(stage of the disease) and sex (40-42). Based on the literature (40-42), the 5 year 
survival rates for women and men with different stages of disease are summarized in 
Table 1.  
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Table 1 Five year survival rates for women and men with different stages of 
lung cancer 
 
 
 
 
 
Lung cancer appears to be a more aggressive disease in men compared to 
women at the same stage of the disease. In SCLC, 60–70% of the patients have 
extensive disease at the time of diagnosis (43). These patients have median survival 
of 7–12 months and the proportion alive at 5 years is approximately 2%. Among 
patients with limited-stage disease, median survival is about 23 months and 5 years 
survival is approximately 12–17% (43). 
2.2 Treatment of lung cancer
Surgical resection, radiotherapy, and CTX are the main curative treatments for 
NSCLC and SCLC. The specific treatment depends on the stage of the cancer, 
histology of the tumor, patients’ preferences, and patients’ physical condition (31). In 
previous years, single treatments were used. Currently, these patients receive a 
combination of treatments (31).  
The treatments for NSCLC and SCLC differ. SCLC is treated primarily with 
CTX or CTX combined with radiotherapy (35). Surgery is offered to only 5% of 
patients with SCLC who are diagnosed in very early stages of the disease (35, 44). In 
NSCLC, surgical resection is offered to patients with stage I, II, and IIIA cancer (2). In 
addition to surgery, patients with NSCLC are offered treatment with CTX or 
 
Gender 
 
Stage I 
 
Stage II 
 
Stage III 
 
Women 
 
47 – 69 % 
 
41 – 63 % 
 
15 – 46 % 
 
Men 
 
33 – 64 % 
 
32 – 52 % 
 
6 – 37 % 
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radiotherapy. Adjuvant treatment is given before and/or after surgery, depending of 
the stage of the disease (37, 45-47).  
Because comorbidity increases with increasing age, the choice of optimal 
treatment for older patients with lung cancer can be challenging (48). The inability to 
predict which elderly patients are “fit” for treatment often results in under treatment 
(23, 48). The likelihood of receiving any kind of treatment for NSCLC decreases 
significantly with age (49). Older patients with lung cancer are less likely to be offered 
surgery (22, 50, 51), even though long term survival rates for older and younger 
patients are comparable (50, 52). Recently, recommendations about how to make 
treatment decisions seems to be based less on patients’ chronological age and more 
on the estimated absolute benefits of treatment, life expectancy, treatment tolerance, 
cognition, presence of comorbidities, and patient preferences (49).  
2.2.1 Surgery 
As discussed above, surgery is the main treatment for NSCLC. This approach 
is used unless the preoperative assessment reveals dissociated disease or the 
primary lesion is inoperable (2, 35, 44).  
Historically, open thoracotomy was the only surgical approach for resection of 
tumor, lung tissue, and lymph nodes (31). During the last two decades, minimally 
invasive access - Video-Assisted Thoracic Surgery (VATS) has become more 
widespread. An increasing percentage of the patients are operated on using this 
method which is less traumatic and seems to offer the same survival advantage as 
open thoracotomy (53). The extent of resection performed during each operation is 
dependent mainly on tumor size and localization. Other factors include pre-exiting 
lung disease and the occurrence of comorbidities. Therefore, the extent of surgery 
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can vary from a wedge resection, segmentectomy, (bi-) lobectomy, to removal of the 
entire lung (pneumonectomy). In addition, reconstruction of airways and blood 
vessels can be performed in order to reduce the amount of lung tissue that needs to 
be removed. While removal of lymph nodes does not appear to improve survival (54), 
guidelines recommend that quite extensive dissection and removal of lymph nodes 
should be performed during these operations (54). If the surgeon determines that the 
tumor is too extensive to remove during surgery, the incision will be closed without 
tumor removal; which is referred to as exploratory surgery (55, 56).  
2.2.2 Adjuvant chemotherapy (CTX) 
Patients are offered CTX before (neoadjuvant) or/and after (adjuvant) surgery 
depending of the stage of their disease (37, 45-47). Because only four of the patients 
who participated in this study received neoadjuvant CTX (i.e. treatment before 
surgery), the focus of this section is on adjuvant CTX. Adjuvant CTX is 
recommended after surgery for patients with more advanced cancer (57). In general, 
the majority of patients with stage II or III NSCLC benefit from adjuvant CTX. 
However, evidence about its benefit in patients with stage 1B is inconclusive (57, 58). 
The Norwegian guidelines (i.e., Nasjonalt handlingsprogram med retningslinjer for 
diagnostikk, behandling og oppfølging av lungekreft) recommend adjuvant CTX for 
stage II or III NSCLC (44), but not for stage 1B.  
Adjuvant CTX is usually started 4 to 6 weeks after surgery (57). The 
Norwegian guidelines recommend that treatment be initiated within 8 weeks (44). 
Vinorelbine with cisplatin is the most common adjuvant CTX regimen for lung cancer 
(57, 58). Usually, the treatment is given over 4 cycles. On day 1, patients receive a 
combination of vinorelbine with cisplatin, then a supplementary dose of vinorelbine 
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on day 8. This cycle is repeated every 21 days. The total duration of adjuvant CTX 
treatment is usually 10 weeks. Not every patient is able to complete all 4 cycles of 
CTX due to the toxic effects of the CTX. In some studies, only 50% of patients were 
able to complete all 4 cycles at the planned doses (57, 58).  
Treatment with CTX can increase symptoms and decrease QOL (57, 58). The 
most frequent toxic effects of adjuvant CTX for NSCLC are neutropenia, anemia, and 
febrile neutropenia (58). Other common side effects are asthenia (i.e., weakness), 
nausea, vomiting, anorexia, and infection (57, 58).  
2.2.3 Postoperative adjuvant radiotherapy (PORT) 
Postoperative adjuvant radiotherapy (PORT) is recommended after adjuvant 
CTX for patients with resected NSCLC who have cancer cells present in two lymph 
nodes (i.e., N2 disease) and disease at Stage III A with N1 – N2 to reduce local 
recurrence (59). If the patient has N0 / pN1 disease, PORT is recommended if there 
is a suspicion of residual cancer (44). PORT is not recommended after 
pneumonectomy. 
Treatment with PORT is normally given 25 to 30 times (44). No studies were 
found that explored symptom burden in patients treated with surgery and PORT, 
respectively (60). However, usual side effects of PORT are dermatitis, esophagitis, 
gastrointestinal symptoms, and neurologic toxic reactions (60). An increased risk of 
death from non-cancer causes has occurred after PORT. However, the toxicity has 
decreased with improvements in planning and in treatment technology (60). Both the 
severe disease and its treatments can cause symptoms in lung cancer patients(61) 
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2.3 Definition of a symptom and symptom experience of oncology patients
A symptom and patients’ symptoms experiences are defined and described in 
different ways (11). In this study, we have chosen to define a symptom, as defined in 
the TMS, as a subjective experience that reflects changes in the biopsychosocial 
functioning, sensation, or cognition of an individual (62). In contrast, a sign is defined 
as any abnormality indicative of disease that is detectable by the individual or others 
(62). Both signs and symptoms are important aspects of health and illness. However, 
a symptom is the patient’s own subjective experience and cannot be measured by 
others. 
Knowledge about symptoms is important for cancer patients for several 
reasons. Symptoms are the most common reason why patients seek healthcare (10). 
Unrelieved symptoms are associated with increased psychological distress, 
decreased physical functioning, and reduced QOL (14). Symptoms can be produced 
by the disease itself, by treatments for the disease, from comorbid medical 
conditions, or from acute injuries (61).  
Each symptom is a multidimensional experience (11). In addition to the 
occurrence of the symptom, its frequency, severity, and associated distress can 
influence the patient’s symptom experience (11). The multidimensionality of the 
symptom experience is important because patients evaluate their symptoms, not only 
by their occurrence, but by making judgements about the severity, cause, treatability, 
and effects of symptoms on their lives (62).  Previous research reports that the most 
prevalent symptoms are not necessarily the most severe or distressing (63, 64). 
Symptom distress is defined as the degree or amount of physical or mental upset, 
anguish, or suffering that in associated with a specific symptom (65).  
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Symptoms can be measured either individually or in combination with other 
symptoms (11). However, patients rarely experience a single symptom. Often, they 
experience multiple symptoms simultaneously (66). For example, patients with 
cancer were found to experience an average of 11 symptoms (67). The risk of 
experiencing multiple, concurrent symptoms after lung cancer surgery are high, since 
these patients can have both cancer-related symptoms as well as symptoms 
associated with surgery. The co-occurrence of multiple symptoms has a significant 
impact on patients’ level of functioning (61). Further research is warranted to 
examine the experience of multiple symptoms in these patients. 
2.4 Symptoms in lung cancer patients before and after surgery
To our knowledge, only five studies have evaluated changes in symptom 
occurrence, severity, and distress before and after lung cancer surgery (14, 16-19). 
All of these studies were published before the present study. Four of these studies 
reported symptoms preoperatively (14, 16-18), and one reported only symptoms after 
surgery (19). The most common preoperative symptoms were: cough, pain, dyspnea, 
loss of appetite, fatigue, and insomnia. One month after surgery, the most frequently 
reported symptoms were: fatigue, nausea, vomiting, insomnia, pain, and dyspnea 
(14, 16-19). The occurrence rates for all of these symptoms increased significantly 
after surgery. However, findings regarding the occurrence rates for the symptom at 4 
to 6 months after surgery were inconsistent. While one study reported that the 
symptom rates at 4 to 6 months after surgery were back to preoperative levels (18), 
others reported that patients still experienced high rates of pain, dyspnea, fatigue, 
and cough at 4 to 6 months (14, 16, 17, 19) .   All five studies used a longitudinal 
design, were well executed, and had a response rate of approximately 80% during 
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the first 4-6 moths (14, 16-19). A higher response rate is preferable because the 
missing data occurs at random (68). In addition, a response rate of approximate 80% 
is acceptable response rate for this patient population. Across these five studies, 
three different questionnaires were used to assess patients’ symptoms. Three of 
studies assed symptoms using the European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the 
EORTC QLQ-LC13 lung cancer-specific questionnaire (16-18). One study used the 
Symptom Distress Scale (SDS) (14) and the other study used the Lung Cancer 
Symptom Scale (LCSS) (19). While all three questionnaires have acceptable 
psychometric properties, the major purpose of the EORTC QLQ questionnaires is to 
measure patients’ QOL and not symptoms.  
While these five studies provided interesting information, several limitations 
warrant considerations. For three of the previous studies the main focus was to 
assess QOL (16-18). These studies reported data on a limited number of symptoms 
and restricted the findings to only occurrence or severity rates for this limited number 
of symptoms (16-18). The first study of 110 patients reported on the severity of only 
two symptoms, namely cough and dyspnea (18). The second study had a limited 
sample (i.e. 60) and a very limited age range (i.e., only patients between 70 and 80 
years) (16). Small sample sizes reduce the studies statistical power; which reduces 
the chance of detecting a true effect, as well as reduces the likelihood that a 
statistically significant result reflects a true effect (68). In addition, the restricted age 
range of the second study, limits the generalizability of the study findings. In the third 
study (n=173), patients were divided into two groups; namely one that remained 
disease free at 2 years and one with patients with recurrent cancer diagnosed during 
follow-up (18). Although, this division is an interesting one, it is difficult to use the 
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results to inform patients about symptoms, because it is difficult to know who will 
have recurrent cancer several years after cancer surgery. 
In the last two of the five studies (14, 19); the primary focus was on an 
evaluation of patients’ symptoms. However, one study focused on symptom distress 
in lung cancer patients who received different treatments (i.e., surgery, CTX, 
radiotherapy). Of note, the surgery group in this sample consisted of only 45 patients 
(14). In the fifth study (19), symptoms severity in 94 patients were assessed at 1 and 
4 months after surgery. The lack of a preoperative symptom assessment makes it 
difficult to distinguish the symptoms that the patients experienced before and after 
surgery. The lack of preoperative symptom assessment is a significant limitation 
because lung cancer patients seem to have a high number of comorbidities than 
other patients (21). These two studier only focused on either symptom distress (14) 
or symptom severity (19). Therefore, we wanted determine if, multiple dimensions of 
the patients’ symptoms experience change from before to following lung cancer 
surgery. 
2.5 Symptoms influence on rehabilitation
This study follows the patients’ from before to five months after surgery. At five 
months after surgery is the period of time when patients start the rehabilitation 
process. Cancer rehabilitation is defined as helping a person with cancer to help 
himself or herself obtain maximum physical, social, psychological, and vocational 
functioning (e.g., optimal working performance) within the limits imposed by the 
disease and its treatment (69). The aim of rehabilitation is to improve the quality of 
survival so that patients will be as comfortable and productive as possible and can 
function at a minimum level of dependency regardless of life expectancy (70).   
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Findings from two studies suggest that, compared to the general population, 
lung cancer patients have a poorer QOL prior to surgery (71, 72). In addition, one 
month after surgery, their QOL decreases compared to preoperative ratings (14, 17, 
18, 73). However, findings regarding changes in QOL scores in months following 
surgery are inconsistent. While some studies found that patients’ QOL returned to 
pre-surgical levels at 3 to 6 months after surgery (16, 18, 73, 74), others reported that 
QOL remained impaired for up to 2 years after surgery (17, 75). A reduction in QOL 
can have a major impact on patients’ lives because it is associated with difficulties in 
fulfilling family roles; reductions in their inability to work; and reductions in their ability 
to participate in common social activities (76). 
If patients experience multiple symptoms in the rehabilitation period, it could 
affect the progress of their rehabilitation, because multiple symptoms are associated 
with significant decreases in functional status and QOL (77). In addition, while 
symptoms are a major problem for patients, they can be a problem for their family 
caregivers. Due to a lack of follow-up care for these patients, symptom management 
often becomes a family member’s responsibility (78). Cancer and its treatments may 
cause physical impairments and psychological distress in survivors (79). While 
limited research is available on lung cancer patients lives after surgery, the findings 
suggest that lung cancer patients have a poorer performance status after surgery 
compared to other cancer patients (80).  
Rehabilitation and physical activity can help patients recover from surgery. 
The European Respiratory Society (ERS) and the European Society of Thoracic 
Surgery (ESTS) clinical guidelines on fitness for radical therapy in lung cancer 
patients (45) recommend early pre- and postoperative rehabilitation in patients with 
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operable lung cancer. Factors that are important in rehabilitation of surgically treated 
lung cancer patients include; increased physical activity, smoking cessation, and 
avoidance of malnutrition (81). In a recent study (82), the introduction of a 
standardized aerobic endurance training program as part of the inpatient 
rehabilitation of patients with lung cancer resulted in significant improvements in both 
physiological and psychological parameters after lung cancer surgery. 
2.6 Comorbidities effect on symptoms
Comorbidity is the presence of one or more additional medical conditions that 
can co-occur with a primary disease or disorder (83). The prevalence of 
comorbidities among lung cancer patients is about twice as high as in the general 
population (21). Findings regarding whether the presence of comorbidities affect 
survival in patients with NSCLC are inconclusive (84, 85). In one study (84), the 
presence of comorbidities reduced survival. In another study (85), no association was 
found. The most common comorbidities in patients with lung cancer are 
cardiovascular disease, emphysema/chronic obstructive pulmonary disease (COPD), 
and hypertension (19, 85).  
The presence of comorbidities is associated with a variety of symptoms and 
can influence the severity of symptoms in lung cancer patients (16, 19). However, 
studies on the relationships between comorbid conditions and the QOL of patients 
following lung cancer report divergent results (86-88). Two of these studies found 
that a higher number of comorbid conditions was associated with poorer physical and 
mental QOL (87, 88). In contrast, another study found no association between 
number of comorbid conditions and QOL (86). Additional research is needed to 
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confirm or refute these findings, and to examine further the impact that comorbid 
conditions have on symptoms. 
2.7 Summary and critique of previous research on symptoms in patients 
undergoing surgery for lung cancer
Few studies have evaluated patients’ symptom burden before and after lung 
cancer surgery (14, 16-19). Symptoms like; cough, pain, dyspnea, loss of appetite, 
fatigue, and insomnia were most common before surgery. The occurrence rates of 
several of these symptoms increased significantly after surgery (14, 16-19). Findings 
regarding further change in symptoms after surgery are inconsistent. The studies 
reported either that the symptom rates were back to preoperative levels 4-6 months 
after surgery (18), or that patients still experienced a high symptom burden (14, 16, 
17, 19). These previous studies provided interesting information (14, 16-19), but had 
several limitations (i.e., reported data on a limited number of symptoms and only 
occurrence, distress or severity rates for these symptoms). However, it seems like 
lung cancer patients have a poorer performance status after surgery compared to 
other cancer patients (80). 
2.8 Theory of Symptom Management (TSM)
The Theory of Symptom Management (TSM) was chosen as the theoretical 
framework for this study (10). The TSM is a middle range theory that can be used to 
guide symptom assessment and treatment in nursing practice. In addition, the TSM 
can be used to guide the development of hypotheses for nursing research (10). A 
middle range theory is a theory with limited scope, that explains a specific set of 
phenomena, in a discipline (89). 
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 The TSM was first introduced as the Symptom Management Model by faculty 
members at the University of California, San Francisco (UCSF) in 1994 (78). The 
theory was further tested and discussed by students and faculty members at UCSF. 
Revised models were published in a journal in 2001 (62), and later as a chapter 
entitled “Theory of Symptom Management” in the third edition of the book “Middle 
Range Theory for Nursing”(10). 
 
Figure 1. Model of the three essential dimensions of the TSM, the symptom 
experience, symptom management strategies, and symptom status outcomes.
(Figure reproduced with permission from John Wiley and Sons. Copyright © 2008. All rights reserved.)
 
As illustrated in Figure 1, the three essential dimensions of the TSM are 
symptom experience, symptom management strategies, and symptom status 
outcomes (10). The symptoms experience dimension is defined as a perception, 
evaluation, and a response to a change in the person’s usual feelings (10). Patients 
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evaluate their symptoms by making judgement about the severity, cause, treatability, 
and effect of symptoms on their lives (62). The symptom management strategies 
dimension is defined as efforts to avert, delay, or minimize the symptom experience. 
Interventions to manage symptoms can be initiated by the health care provider or by 
patient or family members. The reduction in symptoms can be done by either 
reducing the frequency, the severity, or the distress associated with a symptom (90). 
The final dimension (i.e., symptom outcome) is defined as a change in a symptom’s 
status. The change in symptom status can be that the symptom is less frequent, less 
intense, or less distressing. Factors like functional status, QOL, comorbidity, and 
morbidity will influence patients’ symptom outcomes. 
The three essential dimensions are nested within the three domains of nursing 
science (i.e., person, environment, health/illness). Personal factors, environmental 
factors, and a person’s health/illness will influence a person’s symptom experience. 
For instance, a woman’s symptom experience is described to vary by age (person 
domain), her cultural beliefs about the symptom (environmental domain), and her 
current state of health (health/illness domain) (10). A simultaneous interaction exists 
among the symptom experience, symptom management strategies, and symptom 
status outcomes.  
The TSM has been used in different ways in several studies (10, 91, 92). 
However, to our knowledge this study is the first to use the TSM in a sample of 
patients with lung cancer who were evaluated before and following surgery. The TSM 
illustrates the complexity of the patients’ symptom experience. The TSM was used 
when the study was planned; it guided both the longitudinal design of the study, the 
selection of questionnaires, and which demographic and clinical characteristics were 
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collected. Further, the TSM guided the data analysis and the interpretation of the 
results. The TSM provided guidance on the important variables to evaluate both in 
this research study and in the clinic. Given the limited amount of evaluation on 
multiple dimensions of the symptom experience of lung cancer patients and how the 
symptoms change from before to following surgery, this study focused on the 
symptom experience dimension. Based on the findings from this study, subsequent 
intervention studies can be planned to decrease symptoms and improve 
rehabilitation outcomes in these patients.
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AIMS OF THE STUDY 
The main aims of this clinical, interdisciplinary, multi-center, and international 
research study with 264 lung cancer patients were to evaluate patients’ symptom 
experiences before and after lung cancer surgery and to explore how demographic 
and clinical factors influenced these symptom experiences. 
The specific aims were: 
The aim of paper 1 was to evaluate for differences in the symptom experience (i.e., 
RFFXUUHQFHVHYHULW\GLVWUHVVEHWZHHQROGHU\HDUVDQG\RXQJHU\HDUV
patients using a multidimensional symptom assessment scale (i.e., Memorial 
Symptom Assessment Scale (MSAS)).  
The aim of paper 2 was to evaluate for changes in symptom occurrence and 
severity from the preoperative period to 1 month after surgery. In addition, the 
associations between select demographic (i.e., age, gender, living situation) and 
clinical characteristics (i.e., preoperative FEV1, comorbidity, stage of cancer, extent 
of surgery, postoperative complications), as well as the number of preoperative 
symptoms, and the number of symptoms reported at 1 month after surgery were 
evaluated. 
The aim of paper 3 was to evaluate for changes in symptom occurrence and 
severity from the preoperative period to 5 months after surgery and to evaluate for 
predictors of symptom occurrence and severity for seven of the most common 
symptoms. 
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4.0 METHODS 
A longitudinal study that included 270 patients with presumptive primary lung cancer 
over 12 months was initiated in 2010. A longitudinal design is appropriate to study a 
phenomenon’s development over time (93). Patients were recruited from three 
University Hospitals in different health regions in Norway. Data on demographic and 
clinical characteristics, comorbidities, symptoms, and QOL outcome were collected 
and used in this thesis. Patients filled in the Memorial Symptom Assessment Scale 
(MSAS), the European Organization for Research and Treatment of Cancer 
(EORTC) QOL questionnaire with its lung specific module (LC13), and the Self-
administered Comorbidity Questionnaire (SCQ) preoperatively, and again at 1 and 5 
months after surgery. Only data from the 3 item dyspnea scale of the EORTC QOL-
LC13 (i.e., SOB at rest, SOB walking, SOB climbing stairs) were used in this thesis. 
Patients were assessed prior to surgery, and at 1, 5, 9, and 12 months after 
surgery. Due to the time constraints of doctoral study, only data from the 
preoperative, one month, and 5 month assessment were analyzed for this thesis. 
Results from the 9 and 12 month assessments will be published after the thesis is 
completed. Most patients completed the preoperative assessment in the hospital. For 
the remaining assessments, patients received the questionnaires at home and 
returned them to the research office by mail. The one and five month time frames 
were chosen to evaluate the patients’ symptom experience following surgery, as well 
as prior to and after the administration of adjuvant CTX.  
4.1 Patients and settings 
 Patients were recruited from three university hospitals in Norway (i.e., Oslo 
University Hospital, St. Olav University Hospital in Trondheim, Haukeland University 
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Hospital in Bergen). The recruitment of patients started in October 2010 at Oslo 
University Hospital (OUS). Patients were recruited on the surgical ward prior to 
surgery (i.e., the pulmonary division at Rikshospitalet, patient hotel at Ullevål). At 
each institution, two nurses were trained to assist with patient recruitment when the 
PhD student was not present. A check list and a description of the information that 
needed to be provided to the patients were developed and used by these recruitment 
nurses (Appendix 1 and 2).  
In November 2010, recruitment started at St. Olav University Hospital and in 
March 2011 at Haukeland University Hospital. The recruitment of patients at these 
clinics was done by nurses in the pulmonary outpatient clinics and in the division of 
thoracic surgery. The PhD student insured that identical procedures were followed at 
all of the recruitment sites. The recruitment of patients was completed in March 2012.  
4.1.1 Inclusion criteria  
Patients were included if they weUHDGXOWV\HDUVRIDJHZHUHDEOHWRUHDG
write, and understand Norwegian; and were scheduled for surgery for primary lung 
cancer. Patients were excluded if they were cognitively impaired; their surgery was 
cancelled; or if the histological examination after surgery revealed that they had 
benign or metastatic disease. The research staff discussed with the responsible 
nurse and physician if the patient was cognitively impaired and if they were able to 
read, write, and understand Norwegian. If the clinicians were uncertain, patients were 
asked if they thought they were able to complete the questionnaires.  
4.2 Study procedures
 Research staff approached the patient and explained the purpose of the study. 
After obtaining written informed consent (Appendix 3), patients completed the 
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enrollment questionnaires (Appendix 4). The majority of the patients (91%) were 
recruited in the hospital one to three days before surgery. The remaining 9% of the 
sample was recruited in the outpatient clinic prior to surgery. At one and five months 
after surgery, patients were sent the study questionnaires and asked to return them 
using a postage paid envelope. The patients who did not return the questionnaires 
were sent one reminder after about 2 weeks. 
When they enrolled in the study, patients were offered support to complete the 
questionnaires from the PhD student or the research nurse; if they expressed 
problems. The patients were given a mobile phone number and an e-mail address 
they could use to contact the staff if they had any questions about or reactions to the 
questionnaires that were mailed to them at 1 and 5 months after surgery (Appendix 
5). The information about the possibility to withdraw from the study was repeated at 
all measurements points. 
4.3 Study Variables and Instruments
Study measures were obtained through a set of multi-item questionnaires. In 
addition, data were abstracted from patients’ charts. Measures and data collection 
time points are listed in Table 2. When the questionnaires were completed and 
returned, the forms were scanned by a company, and the results were transformed to 
a SPSS data file. Then, the PhD student checked the questionnaires against the 
scanned data file for any errors.  
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Table 2. Measures and data collection time points 
Concepts 
measured
Instruments Data source Study months         
0          1       5          
Patient 
demographics 
Study specific Qnaire / 
charts 
X         X       X          
Clinical and 
medical 
information 
Study specific Qnaire / 
charts 
X         X       X          
Comorbidity SCQ Charts X                   X         
Symptoms 
(general) 
MSAS Qnaire X          X      X         
Quality of life  EORTC QLQ-
C30+LC13  
Qnaire X          X      X          
4.3.1 Demographic and clinical characteristics 
 Information about demographic and clinical characteristics were collected 
either from the patients or from their medical records. Patients provided information 
on gender, marital status, living situation, level of education, and employment status. 
Patients’ medical records were reviewed for information on age, lung function, height, 
weight, and use of preoperative medications, tumor histology, type of surgery, and 
TNM classification (94). A case report form (CRF) was developed to ensure that this 
information was collected from the medical records of all patients (Appendix 1). The 
PhD student or the research nurse completed the CRF based on information found in 
the patient’s medical record. The PhD student picked up the CRFs at the different 
hospitals and brought the forms to OUS. The PhD student evaluated all of the CRF 
forms for completions and obtained any missing data prior to entering the information 
into the SPSS database. 
Information on smoking status was collected at all three assessments. The 
initial information on smoking status (i.e., pre-operative assessment) was obtained 
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from the patients’ medical records. At the 1 and 5 month assessments, the patients 
provided information about smoking. Preoperative information about smoking status 
included: when they started and eventually stopped smoking and the number of 
cigarettes smoked daily. This information is important for the calculation of number of 
pack-years, which is the unit to measure the amount a person has smoked over time. 
One pack-year is 20 cigarettes smoked/day for one year (95). Based on information 
about smoking history, the patients were divided into three groups; never smoked, 
previous smokers, and current smokers. At one and 5 months after surgery, the 
patients were asked if they were smoking (i.e., yes/no) and if they had stopped 
smoking in the period since the last assessment.  
Patients’ lung function was measured by spirometry preoperatively and their 
FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) values 
were recorded in their medical records. FVC is the volume of air that can forcibly be 
blown out after full inspiration. FEV1 is the volume of air that can forcibly be blown 
out in the first second after full inspiration. Predicted normal values for FEV1 and 
FVC are calculated based on an individual’s age, sex, height, weight, and ethnicity. 
By comparing the measured FEV1 and FVC with the predicted normal values, the 
percent of expected FEV1 and FVC were calculated (96). 
Patients’ height and weight were recorded from the medical records. Body 
mass index (BMI) was calculated. BMI is a formula that determines whether an 
individual has the correct weight for their height (97).  
4.3.2 Comorbidity questionnaire  
To measure comorbidity, the Self-administered Comorbidity Questionnaire 
(SCQ) was chosen because it was used in another study of Norwegian cancer 
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patients and found to be a useful and reliable scale (98, 99). The SCQ was 
completed at the preoperative and 5 month assessments (Appendix 4). The SCQ 
includes 16 common comorbidities and three optional conditions (100). Patients 
indicated whether or not they had the comorbid condition (yes/no); if they had the 
condition they were asked if they received treatment for it (yes/no); and finally if it 
limited their activities (yes/no). The SCQ can be scored in two different ways (i.e., a 
sum score, a total score). The sum score is a count of the number of comorbid 
conditions and can range from 0 to 19. The total SCQ-19 score ranges from 0-57. An 
individual can receive a maximum of 3 points for each medical condition: 1 point for 
the presence of the condition, another point if he/she receives treatment for it, and an 
additional point if the condition causes a limitation in function. Because the SCQ 
contains 16 defined medical conditions and 3 optional conditions, the maximum 
score totals 57 points if the open ended items are used and 48 points if only the 
close-ended items are used (100, 101).  A higher total score indicates a more severe 
comorbidity profile.  
The SCQ was used to assess comorbidity in Norwegian oncology patients in 
previous studies (98, 99). The SCQ was translated into Norwegian using a standard 
forward backward translation procedure. The SCQ was tested on medical and 
surgical patients; test-retest reliability of the SCQ was shown to be 0.94 calculated by 
the intraclass correlation coefficient and 0.81 by the Spearman correlation coefficient 
(100).  
4.3.3 Symptoms assessment scale 
Several instruments are available to measure multiple symptoms in cancer 
patients. In one review (67), three questionnaires were considered to be valid and 
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reliable instruments to measure multiple symptoms in cancer patients at different 
stages of their disease. The three instruments were: Symptom Distress Scale (102), 
M. D. Anderson Symptom Inventory (103), and Memorial Symptom Assessment 
Scale (MSAS) (90). The Symptom Distress Scale is a 13-item self-report instrument 
that assesses the level of distress associated with 13 symptoms. The M. D. 
Anderson Symptom Inventory measures the severity of 10 physical symptoms, three 
psychological symptoms, and six interference items (103). The MSAS assesses the 
occurrence, frequency, severity, and distress of 32 symptoms (90). The MSAS was 
selected because it assesses a broad range of symptoms across multiple dimensions 
of the symptom experience. 
The Memorial Symptom Assessment Scale (MSAS) is a patient-rated 
instrument that was developed to provide multidimensional information about 
common symptoms (Appendix 4). The scale contains a list of 32 physical and 
psychological symptoms. Patients completed the questionnaire prior to surgery and 
at 1 and 5 months. Patients were asked to indicate whether or not they had the 
symptom during the past week (i.e., symptom occurrence). If they experienced the 
symptom, they were asked to rate its frequency, severity, and distress. Symptom 
frequency was rated using a four-point Likert scale (1= rarely, 2 = occasionally, 3 = 
frequently, 4 = almost constantly). Symptom severity was rated using a four-point 
Likert scale (1= slight, 2 = moderate, 3 = severe, 4 = very severe). Symptom distress 
was rated using a five-point Likert scale (i.e., 0 = not at all, 1 = a little bit, 2 = 
somewhat, 3 = quite a bit, 4 = very much).  
The MSAS is a reliable and valid instrument for the assessment of symptom 
occurrence, severity, and distress (90). During its development the validity of MSAS 
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was tested using a number of approaches. To test the concurrent validity of the 
MSAS, relationships between symptoms scores and functional status (measured 
using the Karnofsky Performance Status (KPS) scale) and QOL (measured using the 
FLIC) scores were evaluated. Patients with an increased symptom burden had lower 
functional status and QOL scores (90). The construct validity of MSAS was evaluated 
by comparing MSAS scores in different subpopulations. As expected, inpatients had 
higher distress scores than outpatients. In addition, patients with more advanced 
disease were more symptomatic than patients with earlier stage disease (90). 
Previous research used the MSAS to evaluate symptoms in Norwegian 
oncology patients (63). It was translated into Norwegian using a standard forward-
backward translation procedure. Before it was used in a longitudinal study with 188 
breast cancer patients (63), it was pilot tested with 10 breast cancer patients. Only 
minor linguistic adjustments were needed after the pilot testing.
4.3.4 Quality of life questionnaire with a lung cancer specific module 
Numerous instruments are available to assess QOL in oncology patients. The 
most frequently used questionnaires to measure the QOL of lung cancer patients 
before and after surgery are the Medical Outcomes Study - Short Form Health 
Survey 36  (SF 36) (55) and the European Organization for Research and Treatment 
of Cancer (EORTC) QOL questionnaire (55, 104). In this study, the EORTC QOL 
questionnaire (Appendix 4) (105) was selected because this questionnaire was 
developed to measure QOL in cancer patients, and to be able to compare the results 
from our study with previous research. In addition, it has a lung cancer specific 
module (i.e., LC13) that measures lung cancer associated symptoms and side effects 
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from treatment (106). However, in this study, only the lung cancer specific module 
(i.e., LC13) was used because it has specific items for lung cancer patients. 
The EORTC QOL core questionnaire consists of 30 items (105). It includes 
five functional scales (i.e., physical, role, emotional, social, cognitive), three symptom 
scales (i.e., fatigue, pain, nausea/vomiting), a global health status/QOL scale, and a 
number of single items that assess additional symptoms and perceived financial 
impact. This cancer specific, multidimensional questionnaire was tested in different 
cultures and was translated into several languages, including Norwegian (107).  
The EORTC QOL-LC13 is a disease specific module, that assesses lung 
cancer specific symptoms including cough, hemoptysis, dyspnea, and pain as well as 
side effects associated with CTX and RT therapy (106). Patients were asked to rate 
the severity of the symptom using a four-point Likert scale (i.e., 1 = not at all, 2 = a 
little, 3 = quite a bit, 4 = very much). Responses to the QLQ-LC13 questionnaire were 
scored according to procedures specified in the EORTC scoring manual (108). 
EORTC QLQ-LC13 was validated in Norwegian patients. It was found to be a 
clinically valid and a useful tool to assess disease- and treatment-specific symptoms 
in lung cancer patients when it was combined with the EORTC QOL core 
questionnaire (106). In this thesis, only the three item dyspnea scale from the 
EORTC QOL-LC13 was used (i.e., SOB at rest, SOB walking, SOB climbing stairs). 
4.4 Statistics 
All analyses were done using SPSS version 20 and STATA Version 13. For all 
tests, a p-YDOXHRIޒZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQLILFDQW'HVFULSWLYHVWDWLVWLFV
were used to present demographic and clinical characteristics of the sample. Means 
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and standard deviations were generated for quantitative variables and frequencies 
and percentages for categorical variables.  
Paper 1 
In the first paper, a cross sectional design was used. Cross-sectional studies 
are appropriate for describing the status of a phenomenon, or the relationship 
between phenomena, at a fixed point in time (93). This paper evaluated for 
GLIIHUHQFHVLQV\PSWRPRFFXUUHQFHVHYHULW\DQGGLVWUHVVEHWZHHQROGHU\HDUV
and younger (<65 years) patients, preoperatively. Mean scores for severity and 
distress ratings were calculated for those patients who reported a symptom. 
Independent Student’s t-tests, Mann-Whitney U tests, and Chi Square analyses were 
used to evaluate for differences in demographic and clinical characteristics between 
the two age groups. Differences between the two age groups in demographic 
characteristics with multiple levels (e.g., employment status) were further examined 
using post hoc contrasts with a Bonferroni correction (68). Post-hoc analyses are 
concerned with finding patterns and/or relationships between subgroups (e.g., 
working full or part-time, being on sick leave or disability, or being retired). 
Logistic regression analysis was used to evaluate the effect of increasing age 
on the occurrence of each symptom. Significant differences in the occurrence of each 
symptom were evaluated using binary logistic regression analyses. To evaluate for 
differences between the two age groups in the severity and distress ratings for each 
symptom, ordinal logistic regression was utilized. Deviance tests were used for the 
binary logistic regression to determine whether the set of covariates improved the fit 
of the model. Ordinal logistic regression was done with bootstrapping that used at 
least 1000 repetitions for each analysis. Bootstrapping is done to assign measures of 
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accuracy to sample estimates (109). Significance was evaluated with bias-corrected 
bootstrapped confidence intervals. 
Paper 2 
The purposes of this paper were to assess for changes in symptom 
occurrence rates and severity scores from the preoperative period to 1 month after 
surgery. Mean scores for severity ratings were calculated for those patients who 
reported a symptom. 
McNemar's tests were used to evaluate for changes in symptom occurrence 
rates (110). This test determined whether changes in symptom occurrence rates in 
one direction were significantly greater than in the opposite direction (i.e., was the 
number of patients who went from not reporting the symptom preoperatively to 
reporting it postoperatively higher than those who went from reporting the symptom 
preoperatively to not reporting it postoperatively). A paired t-test was used to 
evaluate for changes over time in symptom severity ratings. This analysis was done 
only for symptoms where patients reported severity scores either preoperatively, 
postoperatively, or on both occasions.  
The General Linear Model procedure was used to determine whether select 
demographic and clinical characteristics, as well as total number of preoperative 
symptoms were associated with the total number of symptoms reported after surgery. 
A multivariable model was created and the analysis was performed twice. First an 
unadjusted analysis was done with all factors in the model. Second, a final model 
was created with the predictors that were significant in the unadjusted model or were 
found to be important covariates to include based on previous research. 
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Paper 3 
This paper evaluated the six most common physical symptoms and the most 
common psychological symptom for changes over time in symptom occurrence and 
severity by using a multilevel growth model (MGM). Symptom occurrence was 
examined using multilevel logistic regression (111). Changes in symptom severity 
were examined with multilevel proportional odds ordinal logistic regression. For both 
types of models, random intercepts were estimated, with the first assessment being 
treated as the baseline (or intercept) for the growth trajectory.  
Unconditional models were examined first to estimate the linear change in the 
symptom reports. Since the growth trajectory might not be only linear, quadratic 
effects were examined. Based on previous research (19), age, gender, comorbidity 
(i.e., SCQ total score), and receipt of adjuvant CTX were included as covariates in 
the conditional models for both symptom occurrence and severity. After identifying 
the best fitting growth trajectory for each symptom, conditional models were fit to 
examine the associations for each of the covariates on the reported symptom 
dimensions at enrollment (i.e., prior to surgery) and on the change in symptom 
dimensions over time (cross-level interaction) (112).  
Supplementary analyzes 
To present more detailed information on the frequency, severity, and distress 
dimensions of this patients’ symptom experience, additional analyses was done and 
are presented in the front (“cappa”). In addition, differences in the symptom 
experience of patients who did and did not receive physiotherapy or rehabilitation 
were evaluated. 
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Mean scores for symptom frequency and distress ratings were calculated and 
presented for all three assessments for those patients who reported a symptom. 
Differences in the total number of symptom at five months were examined with paired 
T test between patients who had and had not received physiotherapy or 
rehabilitation. 
4.5 1.1 Ethical considerations
This study was approved by the Regional Ethical Review Committee (REK), with 
REK number 2010/1508b, and supported by the Institutional Review Boards 
(Personvernombudet) at the hospitals involved in the study. New REK permissions 
were obtained before the recruitment of patients started at Haukeland University 
Hospital. Patients signed an informed consent when they agreed to participate in the 
study (Appendix 3).  
The patients who participated in this study were a vulnerable group, because 
lung cancer is a serious and stigmatizing illness. They were included in the study at a 
difficult time of their life; shortly after being diagnosed with cancer and facing surgery. 
To ensure that patients did not feel pressured to participate in the study; they were 
asked by a familiar nurse if they wanted information about the study. An information 
brochure were developed and given to the patients to inform them about the study 
(Appendix 6). 
Some of the questions about psychological factors could be sensitive for 
patients to answer, and this could be experienced as a burden for the patients. 
Patients were informed that participation in the study was voluntary, that their 
treatment would be the same whether they participated or not, and that they could 
withdraw from the study at any time. The patients were given an email address and a 
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telephone number when they enrolled in the study. This information was repeated in 
the information letter that was sent with the questionnaires (Appendix 5). If the 
patients did not answer the questionnaire, they were sent only one reminder. Patients 
who did not respond to two consecutive assessments were not sent any additional 
questionnaires. If the patient contacted the PhD student with questions, they were 
given the necessary information about the topic, and were informed about the 
possibility to withdraw from the study.  
To ensure the patients’ anonymity and confidentiality, the questionnaires were 
marked with a code. The list that connected patients’ names and the code was kept 
in a locked safe in a locked room in the hospital. The data files were stored according 
to Oslo University Hospitals’ safety rules. 
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*In study 1 was patients with exploratory  
surgery included (n=270) 
Figure 2. Flow chart inclusion and exclusion. 
n = 419 
Presumptive primary lung cancer Reasons for exclusion (n=44):  
- 8 cognitive impaired 
- 7 not able to read/understand Norwegian 
- 29 not asked due to lack of time or 
resources n = 375 
Asked to participate Reasons for exclusion (n=68):  
- 68 declines participation 
n = 307 
Agreed to participate 
Reasons for exclusion (n=22):  
- 5 metastatic disease 
- 7 benign disease 
- 4 surgery cancelled 
- 6 exploratory surgery  
 n =264 (92%) * 
Preoperative assessment Reasons for exclusion (n=36):  
- 4 died 
- 4 withdrew from the study 
- 28 did not return questionnaires 
n = 228 (80%) 
1 month assessment 
Reasons for exclusion (n=16):  
- 6 died 
- 1 withdrew from the study 
- 9 did not return questionnaires 
n = 212 (74%) 
5 month assessment 
n = 285 
Enrolled in study Initial dropout (n=21) 
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5.0 RESULTS 
5.1 Sample
Of the 419 patients with presumptive primary lung cancer, 375 were eligible to 
be approached about participation, and 307 agreed to participate (81% response 
rate). Based on our pre-specified exclusion criteria, 15 patients were excluded (i.e., 5 
for metastatic disease, 7 for benign disease, 4 had surgery cancelled,) (Figure 2). 
The 6 patients who had exploratory surgery were included in the sample in paper 1 
(n=270) because this paper presented preoperative data. However, these patients 
were excluded from the preoperative sample in papers 2 and 3, because they did not 
have a tumor removed (n=264). The recruitment was planned so that all eligible 
patients would be asked about participation, but due to lack of time or resources, 29 
of the potential patients were not invited to participate. 
 The demographic and clinical characteristics of the patients at the different 
assessment points are summarized in Table 3. Approximately 45% of the patients 
smoked preoperatively, 10% after one month, while 13% smoked five months after 
surgery. The number of patients who worked decreased from 30% preoperatively to 
9% five months after surgery (Table 3). In this study, 77% of the patients were 
transported to a local hospital before coming home. At five months, 36% of the 
patients were using analgesics, compared to 15% at the preoperative and 75% at the 
postoperative assessments (i.e., one month).  
A total of 85% of the patients reported comorbid conditions; 23% had one 
comorbid condition, 25% had 2, and 37% had 3 or more comorbid conditions. The 
most frequent comorbid condition was back/neck pain (46%), followed by 
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hypertension (34%), and COPD (32%). Approximately 30% of the patients received 
CTX after surgery. 
Patients who declined participation in the study was significantly older (mean 
DJH\HDUV6'SޒFRPSDUHGWRWKRVHZKRSDUWLFLSDWHG1RJHQGHU
differences were found between participants and non-participants (p=0.41). Of the 
264 who completed the preoperative assessment; 10 patients died during the first 5 
months.  
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Table 3: The demographic and clinical characteristics of the patients at the 
different assessment points.
 
Characteristics 
Assessment 
 
Preoperative 
n=270* 
1 month 
n=228 
5 months 
n=212 
Mean (SD) Mean (SD) Mean (SD) 
Age (years) 65.8 (8.5) 65.8 (8.5) 66.1 (8.3) 
SCQ-19 score 4.4 (3.8) 4.3 (3.8) 4.2 (3.8) 
Mean number of MSAS 
symptoms 
9.1 (7.0) 12.8 (6.7) 11.0 (6.9) 
 % (n) % (n) % (n) 
Gender- Female 41.5 (112) 43.4 (99) 42.9 (91) 
Lives alone 23.1 (59) 23.1 (50) 21.7 (46) 
Partnered/married 73.0 (189) 73.4 (160) 72.9 (148) 
Education 
 Primary School 
 Secondary school 
 University/ College 
 
36.6 (94) 
47.1 (121) 
16.3 (42) 
 
36.6  (79) 
48.1 (104) 
15.3  (33) 
 
35.6 (72) 
48.0 (97)  
16.3 (33)  
Employment status: 
Full or part-time 
Sick leave or disability 
Retired or other   
 
29.9 (60) 
23.9 (48) 
43.9 (93) 
 
13.1 (26) 
32.2 (64) 
54.8 (109) 
 
8.8 (17) 
35.2 (68) 
56.0 (108) 
Smoking (% yes) 45.3 (96) 
 
10.1 (20) 12.6 (26) 
Tumor type 
 Adenocarcinoma 
 Squamous cell 
 Small cell 
 Carcinoid 
 Other 
 
56.3 (152) 
30.7(83) 
 2.2(6) 
 2.2(6) 
 8.5 (23) 
 
56.1 (128) 
30.7 (70) 
 2.2 (5) 
 2.2 (5) 
 8.8 (20) 
 
55.2 (117) 
30.7 (65) 
2.4 (5) 
2.8 (6) 
9.0 (19) 
Stage of cancer disease 
 IA 
 IB 
 II 
 IIIA 
 IIIB - IV 
 
32.0 (80) 
31.6 (79) 
18.8 (47) 
16.0 (40) 
1.6 (4) 
 
31.8 (68) 
33.2 (71) 
18.7 (40) 
15.9 (34) 
0.5 (1) 
 
33.3 (66) 
31.8 (63) 
19.7 (39) 
14.6 (29) 
0.5 (1) 
Type of surgery 
 Lobectomy 
 Bi-lobectomy 
 Pneumonectomy 
 Wedge resection 
         Video-assisted    
         thoracoscopic surgery   
         Exploratory surgery 
 
183 (68.0) 
19 (7.1) 
23 (8.6) 
24 (8.9) 
14 (5.2) 
 
2.2 (6) 
 
69.3 (158) 
6.1 (14) 
9.6 (22) 
8.8 (20) 
6.1 (14) 
 
0 
 
67.5 (143) 
7.1 (15) 
9.4 (20) 
9.4 (20) 
6.6 (14) 
 
0 
Used analgesic (% yes) 14.6 (31) 
 
74.8 (169) 36.0 (73) 
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5.2 Results of paper 1
 This paper evaluated for differences in symptom occurrence, severity, and 
GLVWUHVVEHWZHHQROGHU\HDUVDQG\RXQJHU\HDUVSDWLHQWVSULRUWRVXUJHU\
No significant differences were found in the total number of symptoms reported by 
older (mean=9.15, SD=7.64) and younger (mean =10.11, SD=6.96) patients. Looking 
at the individuals with symptoms; in the bivariate analyses, older patients reported 
VLJQLILFDQWO\ORZHURFFXUUHQFHUDWHVIRUGLIILFXOW\FRQFHQWUDWLQJSޒIHHOLQJGURZV\
(pޒIHHOLQJQHUYRXVSޒIHHOLQJVDGSޒDQGZRUU\LQJSޒ,QWKH
multivariable analyses, after adjusting for employment status, analgesic use, and the 
use of anticholinergic medicines, older patients reported a significantly lower 
occurrence rate for only one symptom, namely feeling drowsy. 
Symptom severity scores ranged from slight to moderate. In the bivariate 
analyses, older patients reported significantly lower severity scores for difficulty 
concentrating (p=.049), feeling nervous (p=.044), and feeling sad (p=.045). In the 
multivariable analyses, only the severity score for feeling nervous (p=.049) was 
significant in that older patients were 71% less likely to report a higher severity score 
for feeling nervous  
 Mean distress scores ranged from a “little bit” to “somewhat”. In the bivariate 
analyses, older patients reported significantly lower distress ratings for five symptoms 
(i.e., feeling drowsy (p=.012), pain (p=.018), lack of energy (p=.029), shortness of 
breath (p=.044), worrying (p=.036)). In the multivariable analyses, only lack of energy 
(p=.035) was significant in that older patients were 71% less likely to report a higher 
distress score.  
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5.3 Results of paper 2
This paper evaluated for changes in symptom occurrence rates and severity 
ratings from the preoperative period to 1 month after surgery. The total number of 
symptoms increased significantly from the preoperative (mean = 9.4) to the 
postoperative (mean = 13DVVHVVPHQWSޒ2IWKHV\PSWRPVWKDW
RFFXUUHGLQRIWKHSDWLHQWVDWPRQWKRIWKHPLQFUHDVHGVLJQLILFDQWO\LQERWK
occurrence rates and severity ratings from the preoperative assessment. The 
RFFXUUHQFHUDWHVIRU62%SޒODFNRIHQHUJ\SޒSDLQSޒIHHOLQJ
GURZV\SޒGU\PRXWKSޒVZHDWVS IHHOLQJEORDWHGS DQG
ODFNRIDSSHWLWHSޒLQFUHDVHGVLJQLILFDQWO\IURPWKHSUHRSHUDWLYHWRWKH
postoperative assessment.  
Severity scores for SOB (CI 0.69 to 1.17), lack of energy (CI 0.74 to 1.21), 
pain (CI 0.86 to 1.28), feeling drowsy (CI 0.64 to 1.03), dry mouth (CI 0.14 to 0.67), 
sweats (CI 0.18 to 0.82), feeling bloated (CI 0.05 to 0.71), and lack of appetite (CI 
1.01 to 1.59) increased significantly from the preoperative to the postoperative 
assessment. The only symptom that had a significant reduction in its severity score 
was cough (CI -0.58 to -0.06). 
In both the unadjusted and final models, the only variable that was associated 
with a higher number of postoperative symptoms was the number of preoperative 
symptoms reported by the patient. 
5.4 Results of paper 3
This paper evaluated for changes in symptom occurrence rates and severity 
ratings from the preoperative period to 1 and 5 months after surgery. The total 
number of symptoms increased significantly from the preoperative (mean=9.1 
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SD=7.0) to the 1 month (meaQ 6' SޒDVVHVVPHQW$WPRQWKVWKH
number of symptoms was lower than at 1 month but significantly higher (mean=11.0, 
6' SޒWKDQDWWKHSUHRSHUDWLYHDVVHVVPHQW 
The patterns in the occurrence and severity of symptoms varied for the seven 
symptom evaluated in this paper. For example, in the unconditional model, 
trajectories for the occurrence of pain, lack of energy, SOB, feeling drowsy, and 
worrying increased significantly from prior to through the first month after surgery and 
then decreased over time. In contrast, the occurrence of cough and difficulty sleeping 
did not change over time. In terms of the patterns observed for the symptom severity 
ratings, in the unconditional model, the severity of SOB at rest and during walking 
and climbing stairs changed over time. SOB when resting, walking, and climbing 
stairs increased significantly from enrollment to one month and then decreased over 
time. In contrast, the severity of cough decreased from enrollment to one month after 
surgery and then increased over time. Of note, severity ratings for pain, lack of 
energy, feeling drowsy, difficulty sleeping, and worrying did not change over time.  
Overall, the four covariates (i.e., comorbidity score, age, gender, receipt of 
adjuvant CTX) influenced the occurrence of symptoms preoperatively. Comorbid 
conditions influenced the occurrence of all symptoms except cough preoperatively 
and it influenced the occurrence of difficulty sleeping over time. 
Patients who were older were less likely to report pain and feeling drowsy 
preoperatively. In addition, age influenced changes over time in the severity ratings 
for SOB when climbing stairs. From the preoperative assessment to one month after 
surgery, younger patients’ severity ratings for SOB when climbing stairs increased 
and then decreased at a faster rate than those of the older patients.  
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In this paper, women reported higher occurrence rates for worrying 
preoperatively, and a greater increase in the severity scores for pain at one month. 
From the preoperative to the one month assessment, women’s pain severity scores 
increased while men’s pain severity scores decreased. The opposite patterns were 
observed from the one month to the 5 month assessment. 
The last covariate; receipt of adjuvant CTX increased the occurrence of the 
following symptoms; lack of energy, difficulty sleeping, pain, and feeling drowsy 
preoperatively, as well as the severity of cough. The administration of adjuvant CTX 
was associated with higher severity ratings for cough at the preoperative assessment 
followed by a decline in the severity ratings for cough and then a subsequent 
increase in the severity of cough. 
5.5 Results of the additional analyses
The additional analyses revealed that the symptoms with the highest 
occurrence rates at the different assessments were not necessarily the most 
frequent, severe or distressing at five months after surgery (Table 4 and 5). The five 
symptoms with the highest occurrence rates at five months were: SOB, lack of 
energy, feeling drowsy, cough, and pain. The five symptoms with the highest 
frequency rates at five months were; problems with sexual interest, SOB, hair loss, 
lack of energy, and changes in skin.  
Problems with sexual interest had the ninth highest occurrence rate at the 5 
months assessment. However, for patients who reported this symptom, it had the 
highest ratings for frequency, severity and distress. Of note, some of the symptoms 
that were rated as very severe or distressing were only experienced by a few 
patients. Symptoms like “I don’t look like myself” and “problems with urination” were 
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among the top five most severe and distressing symptoms, but were only 
experienced by a limited number of patient (i.e., n=13 and n= 33, respectively). While 
different symptoms were among the most common as well as among the most 
frequent, severe or distressing symptom, two symptoms, namely SOB and lack of 
energy were among the top five for all of the symptom dimensions at 5 months.  
Additional analysis was done to further explore patients’ symptom experience 
at five months for the 8 symptoms with the highest severity and distress ratings 
(Table 6 and 7). The purpose of this analysis was to obtain more detailed information 
about the distribution of the severity and distress scores for these symptoms. These 
analyses revealed that the majority of the patients reported relative low levels of 
severity and/or distress for these symptoms. However, between 5% and 10% of the 
patients reported high severity and/or distress scores for the 8 symptoms. These 
patients may be at particularly high risk and warrant more aggressive symptom 
management. SOB and lack of energy were the two symptoms associated with high 
severity and distress ratings for the majority of the patients. 
Finally, an analysis was done that compared the total number of symptoms at 
five months, between patients who did and did not receive physical therapy and/or 
rehabilitation. The purpose of this analysis was to evaluate if physiotherapy and/or 
rehabilitation reduced the number of symptoms. Forty-two percent of the patients 
(n=89) received physical therapy and/or inpatient rehabilitation after surgery. When 
the total number of symptoms was compared between patients’ who received and did 
not receive physiotherapy/rehabilitation, no differences were found. In addition, no 
between group differences were found on gender, age and number of comorbidities.  
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Table 4. The symptoms with the highest occurrence rates and the highest frequency, 
sever, frequent, and distress rating at different assessment points 
OCCURRENCE RATES
Rank† Symptoms Preoperative 
(n=264)
1 month 
(n=228)
5 months 
(n=212)
% of patients % of patients % of patients 
1 Shortness of breath 51.1 85.5 78.8 
2 Lack of energy 54.9 83.8 70.8 
3 Feeling drowsy 52.7 82.5 67.0 
4 Cough 64.0 61.4 59.9 
5 Pain 38.6 83.3 55.7 
6 Difficulty sleeping 46.6 51.8 50.5 
7 Feeling bloated 44.7 51.8 49.1 
8 Dry mouth 45.8 58.8 48.1 
9 Problems with sexual int. 43.6 49.6 46.7 
10 Worrying 51.5 56.6 46.7 
FREQUENCE RATINGS¤
Rank† Symptom Preoperative 1 month 5 months 
Mean score 
(SD) 
Mean score 
(SD) 
Mean score 
(SD) 
1 Problems with sexual interest 2.63 (1.03) 2.87 (1.13) 2.79 (.99) 
2 Shortness of breath 2.47 (.92) 2.64 (.93) 2.60 (.94) 
3 Hair loss 2.58 (1.22) 2.56 (1.29) 2.54 (1.14) 
4 Lack of energy 2.50 (.97) 2.71 (.88) 2.52 (.86) 
5 Changes in Skin 2.05 (.90) 2.06 (1.09) 2.52 (.95) 
6 Feeling drowsy 2.36 (.80)  2.47 (.82) 2.36 (.80) 
7 Pain 2.60 (1.06) 2.48 (.97) 2.28 (.96) 
8 Feeling bloated 2.14 (.80) 2.18 (.84) 2.28 (.87) 
9 Changes in way food tastes 1.75 (.91)  2.46 (1.03) 2.23 (.83) 
10 Difficulty sleeping 2.49 (.90) 2.55 (.91) 2.21 (.92) 
SEVERITY RATINGS*
Rank† Symptom Preoperative 1 month 5 months
Mean score 
(SD) 
Mean score 
(SD) 
Mean score 
(SD) 
1 Problems with sexual int. 2.46 (.90) 2.43 (.85) 2.53 (.90) 
2 I don’t look like myself 2.25 (.87) 2.27 (.80) 2.38 (.96) 
3 Shortness of breath 2.14 (.74) 2.20 (.73) 2.25 (.82) 
4 Lack of energy 2.08 (.74) 2.21 (.74) 2.19 (.69) 
5 Problems with urination 2.07 (.92) 1.77 (.85) 2.15 (.83) 
6 Constipation 2.06 (.72) 2.11 (.90) 2.14 (.81) 
7 Hair loss 2.64 (1.15) 2.36 (1.13) 2.12 (1.09) 
8 Changes in Skin 1.62 (.62) 1.77 (.60) 2.10 (.63) 
9 Difficulty sleeping 2.31 (.84) 2.23 (.77) 2.09 (.73) 
10 Difficulty Swallowing 1.92 (1.08) 1.79 (.88) 2.09 (1.07) 
 
¤Frequency ratings = rarely (1), occasionally (2), frequently (3), almost constantly (4). *Severity 
ratings= slight (1), moderate (2), severe (3), very severe (4). †The ranking were done based on the 
results of the assessment at 5 months. 
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Table 5. The symptoms with the highest distress ratings at different assessments 
DISTRESS RATINGS† 
Rank Symptom Preoperative 1 month 5 months
Mean score (SD) Mean score 
(SD) 
Mean score 
(SD) 
1 Problems with sexual 
interest 
1.78 (1.36) 1.36 (1.12) 1.70 (1.19) 
2 Lack of energy 1.57 (1.07) 1.58 (.97) 1.62 (1.01) 
3 I don’t look like myself 1.71 (1.38) 1.63 (1.46) 1.62 (1.26) 
4 Shortness of breath 1.73 (1.09) 1.72 (1.12) 1.59 (1.11) 
5 Problems with urination 1.35 (1.25) 1.00 (1.15) 1.45 (1.30) 
6 Difficulty Swallowing  1.14 (1.35) 1.29 (1.13) 1.45 (1.18) 
7 Pain 1.63 (1.09) 1.36 (.93) 1.42 (.91) 
8 Feeling sad 1.63 (1.07) 1.20 (.87) 1.40 (1.00) 
9 Worrying 1.65 (1.07) 1.45 (1.02) 1.38 (.91) 
10 Constipation 1.15 1.34 1.35 
†Distress ratings = not at all (0), a little bit (1), somewhat (2), quite a bit (3), very much (4). † The 
ranking were done based on the results of the assessment at 5 months.  
Table 6. Severity ratings at 5 months 
Symptom  
Sample 
size 
 
Mea
n 
scor
e 
Severity ratings % (n) 
Slight Moderate Severe Very 
severe 
Shortness of breath 131 2.25 15 (20) 53 (69) 24 (29) 7 (9) 
Lack of energy  118 2.19 12 (14) 62 (73) 22 (26) 4 (5) 
Feeling drowsy 107 2.0 20 (21) 62 (66) 17 (18) 2 (2) 
Cough 100 1.81 34 (34) 52 (52) 13 (13) 1 (1) 
Pain 100 1.98 22 (22) 59 (59 17 (17) 2 (2) 
Difficulty sleeping 77 2.09 14 (18) 58 (45) 20 (15) 4 (3) 
Worrying 82 1.84 32 (26) 54 (44) 12 (10) 2 (2) 
Problems with sexual int. 74 2.53 10 (7) 46 (34) 27 (20) 18 (13) 
†Severity ratings= slight (1), moderate (2), severe (3), very severe (4) 
Table 7.  Distress ratings at 5 months
Symptom  
Sample 
size 
 
Mean 
score 
Distress ratings % (n) 
Not At 
All 
A Little 
Bit 
Some 
what 
Quite 
A Bit 
Very 
Much 
Shortness of breath 128 1.59 13 (17) 43 (55) 23 (29) 14 
(18) 
7 (9) 
Lack of energy  115 1.62 10 (11) 42 (48) 32 (37) 10 
(12) 
6 (7) 
Feeling drowsy 105 1.10 29 (30) 43 (45) 20 (21) 7 (7) 2 (2)  
Cough 92 0.97 34 (32) 47 (43) 11 (10) 7 (6) 2 (2) 
Pain 95 1.42 11(10) 51 (48) 30 (28) 5 (5) 4 (4) 
Difficulty sleeping 81 1.31 22 (18) 41 (33) 26 (21) 6 (5) 5 (4) 
Worrying 82 1.38 11 (9) 55 (45) 23 (19) 7 (6) 4 (3) 
Problems with sexual 
interest 
76 1.70 16 (12) 34 (26) 22 (17) 20 
(15) 
8 (6) 
†Distress ratings =not at all (0), a little bit (1), somewhat (2), quite a bit (3), very much (4) 
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6.0 DISCUSSION
6.1 Methodological considerations 
6.1.1 Sample 
Approximately 850 patients went through lung cancer surgery in Norway 
during the period of this study. With 270 patients included in the present study (113), 
approximately 30% of the total number of lung cancer patients who underwent 
surgery in Norway were included. This finding suggests that this sample is 
representative of surgically treated lung cancer patients in Norway. However, 
patients from only 4 of the 8 hospitals performing this surgery in Norway were 
included. Across these 4 hospitals, 29 of the eligible patients were not invited to 
participate due to lack of time or resources. The main reason for not asking these 
patients to participate was because they came to the hospital on Sunday afternoon. 
No differences in demographic characteristics were found between these patients 
and the ones who were invited to participate in this study. 
The sample sizes varied at the different measurement points because of the 
reasons listed in Figure 2. The dropout rate over the first 5 months of the study was 
approximately 15% (i.e. 5 withdrew their informed consent, 35 did not answer the 
mailed questionnaires). This attribute could cause sampling bias; because a major 
problem with self-report data is that data may be lost from patients who are not doing 
well (23). However, no differences in demographic and clinical characteristics were 
found between patients who did and did not complete the 5 month assessment. 
To increase the sample’s homogeneity, all of the patients in this study were 
diagnosed with primary lung cancer; they were all surgically treated; and none of 
them had any evidence of metastases when they were included in the study. The 
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reason for only including surgically treated lung cancer patients without metastasis, 
was that the prognosis for these patients is different than for inoperable lung cancer 
patients and/or for patients with metastatic lung cancer (31). This inclusion criteria 
was considered as important when following patients for a relatively long period of 
time after surgery. 
The patients in this study had different stages of disease, had different 
histological types, and had different types of surgery; which provides a representative 
and varied sample of lung cancer patients. The distribution of types of surgery are 
quite similar to the total distribution of lung cancer surgery in Norway that was 
provided by the Norwegian Association for Cardiothoracic Surgery (113). Even 
though the distribution of VATS in our sample was similar to the Norwegian sample, 
some countries have a higher percentage of VATS (114). This difference may 
decrease the generalizability of the study findings to other countries because VATS 
seems to improve patients’ perioperative outcomes, as well as reduce complication 
rates and duration of hospitalization (53, 55). However, the significance of these 
differences is uncertain. A meta-analysis reported a lack of well-designed 
randomized controlled trials and longitudinal studies that assessed for differences in 
QOL outcomes between patients who underwent a VATS compared to a 
thoracotomy (53).   
6.1.2 Recruitment of patients 
The PhD student recruited the majority of the patients (54%). The remaining 
patients were recruited by nurses who were trained in the recruitment processes. To 
ensure that the enrollment procedure was standardized, a written procedure for the 
recruitment process was given to the nurses who assisted with recruitment (Appendix 
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2). The procedures for recruitment were slightly different at each hospital, due to 
different hospitalization practice and work schedules for the nurses assigned to do 
the recruitment. However, these differences did not seem to influence the percentage 
of patients recruited to the study at each hospital.  
The majority of the patients (91%) were recruited from the hospital where they 
had the surgery, one to three days before surgery. They were asked to complete the 
study questionnaires the day before surgery. This time may be a vulnerable period 
for the patients and may influence their responses. The timeframe was chosen for 
practical reasons because the decision about the tumor’s operability was often made 
shortly before surgery at a local hospital. Therefore, it was difficult to contact the 
patient before surgery. We made the decision to recruit the patients at the time of 
hospitalization. Another advantage to this approach is that the patients had to wait for 
different tests and for different examiners on the day before the surgery. Therefore, 
they had time to complete the questionnaires.  
The remaining 9% of the sample was recruited in the outpatient clinic after 
receiving their cancer diagnosis, approximately 1-4 weeks prior to surgery. They 
completed the enrollment questionnaires at home and mailed it back to the hospital 
where they were recruited. The fact that the patients completed questionnaires at 
different times and places may influence their responses. However, all of the patients 
had received information about a serious cancer diagnosis and were awaiting 
surgery which is a quite stressful period for them. Even if this sample was small 
(n=24), an analysis was done to evaluate for differences in the patients based on 
location of recruitment. No significant differences in symptom occurrence rates and 
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frequency, severity, or distress ratings were found between the groups recruited in 
the outpatient clinic and in the hospital. 
6.1.3 Data collections 
The majority of the demographic and clinical information was found easily in 
the medical records. However, information about the patients’ smoking history was 
somewhat incomplete in the medical records in some cases. In many cases, 
information on previous smoking history and number of cigarettes smoked daily was 
not recorded. This information is important for the calculation of number of pack-
years. Initially, we planned to evaluate if the number of pack-years influenced 
symptom burden, but due to the incomplete data this analysis was not possible. 
When designing this study, the selection of questionnaires was discussed. It 
was important to collect sufficient data, but at the same time to limit the number of 
questions to reduce respondent burden (93). Because of the paucity of research 
about changes in symptom burden over time in patients with lung cancer, we chose 
to focus our data collecting on symptoms. This approach would provide the 
foundation for future research. Because we are a research group that is focused on 
the evaluating of symptoms in different patient groups, we chose to use similar 
questionnaires across these studies for comparative purposes. One questionnaire 
that was not included was the Karnofsky Performance Status scale (KPS), which 
assesses the patients’ level of physical functioning. The KPS scale was not used 
because the EORTC QOL-LC13 assessed how SOB influenced patients’ ability to 
function (i.e., SOB at rest, SOB walking, SOB climbing stairs). In retrospect, having 
data from the KPS scale would have allowed us to compare the findings from this 
study to other symptom studies that included this scale (67). In addition, information 
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on symptom management interventions should have been collected. With these data, 
analyses could have been done to evaluate for differences in the symptom 
experience of patients who did and did not receive treatments for their symptoms.  
Furthermore, we knew at the start of the study that the majority of the patients 
would be elderly. Therefore, efforts were made to design questionnaires that were 
easy to read. This approach was used because poorly designed questionnaires can 
make the respondent confused and affect the quality of the study results (93). When 
completing the MSAS, some patients did not answer all of the questions. This 
questionnaire asks patients to indicate whether or not they had the symptom during 
the past week (i.e., symptoms occurrence). If they experienced the symptom, they 
were asked to rate its severity and distress. Some patients did not indicate if they had 
the symptoms, even though they indicated that it was a severe or distressing 
symptom. As was done in a previous study (63), in these cases, we chose to 
interpret that they experienced the symptom, because the first question about 
symptom occurrence may have been misunderstood.
6.1.4 Design and statistical analysis 
This thesis presents data at 3 measurement points. Patients were enrolled 
preoperatively and followed for 5 months. One challenge with longitudinal studies is 
to decide on the number of and the interval between the assessments. Too many or 
too frequent assessments may be a burden for the patients. However, too long a time 
between the assessments may result in lost information about changes in the 
phenomenon of interest (93). In this study, data were collected before and 1 and 5 
months after surgery, to measure the symptoms before and after the potential 
administration of adjuvant CTX. Adjuvant CTX is usually started 4 to 6 weeks after 
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surgery and the duration of treatment is normally 10 weeks (57). However, it may be 
that we lost some information about changes in symptoms in the 4 month interval 
between the 1 and 5 month assessment. For instance, when symptoms decreased 
from 1 month to 5 months; it is not clear if the symptom decreased steadily from 1 to 
5 months or if symptom remained high until 4 months and then decreased. 
Because the three papers had different foci and different assessments points 
were included, different statistical procedures were used in each paper to answer its 
specific goal. The statistical analyses varied based on the type of data collected and 
if the study was cross sectional or longitudinal. On MSAS, the ratings of symptoms 
occurrence, frequency, severity, and distress are all categorical. However, while 
symptom occurrence is a dichotomous variable with two categories (i.e., yes, no), the 
frequency, severity, and distress were ordinal variables measured using four or five 
point Likert scales. These differences in the variables required the use of different 
types of statistical analyses.
 In the first paper, a cross sectional design was used. This design was the best 
approach because we wanted to describe patients’ symptoms before surgery. The 
benefit of a cross-sectional design is that it allows researchers to compare many 
different variables at the same time. A limitation with cross-sectional studies is that it 
does not provide definite information about cause-and-effect relationships (93). A 
comparison was done of the occurrence rates and severity and distress ratings of 32 
symptoms between younger and older patients before surgery. In order to evaluate 
the effect of age on the severity of each symptom, we divided the patients into two 
age groups and utilized ordinal logistic regression. Because surgery is not done on 
severely ill patients (31), and all the patients in this study had surgery, some of the 
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symptoms had very low occurrence rates. Since regression analyses should not be 
performed on small samples (68), this analysis was performed only when 40 patients 
reported the occurrence of a specific symptom. In addition, symptom severity and 
distress ratings were not analyzed if fewer than 10 responses were available in the 
upper two categories. With this approach, we may have lost some information about 
age differences in patients’ symptom experience. However, this conservative 
approach to the statistical analysis provided confidence that we would not draw 
erroneous conclusions.  
The second paper evaluated for changes in symptom occurrence and severity 
from the preoperative period to 1 month after surgery. To make the presentation of 
these data manageable and clinically relevant, only the eleven symptoms that 
occurred in more than 50% of the patients at the postoperative assessment were 
analyzed and the analysis of symptom distress was not included. However, by not 
including analyses of the distress and frequency ratings in papers 2 and 3, we lost 
some information about two dimensions of the patients’ symptom experience. Data 
on patients’ distress and frequency ratings are presented in this thesis to give a more 
comprehensive picture of the patients’ symptom experience. 
Different analysis methods can be used to evaluate for changes in symptom 
occurrence rates from before to 1 month after surgery. Since symptom occurrence is 
a dichotomous variable, the McNemar's test was chosen. The McNemar's test 
determined whether changes in symptom occurrence rates in one direction were 
significantly greater than in the opposite direction. McNemar's test provides more 
detailed information than a Chi-square test that was another alternative (68) side 
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220. The McNemar's test was done because some symptoms were not present at 
the preoperative assessment and or 1 month assessment and vis a versa. 
In paper two, a general linear model was used to determine whether select 
demographic and clinical characteristics, as well as the number of preoperative 
symptoms, were associated with the total number of symptoms reported after 
surgery. The specific characteristics were used because previous research found 
that they were associated with reductions in QOL after surgery (55, 86, 115). 
Predictors from QOL studies were chosen because of the paucity of symptoms 
studies in surgically treated lung cancer patients. While the analysis was done with a 
number of demographic (i.e., age, gender, living situation) and clinical characteristics 
(i.e., preoperative FEV1, comorbidity, stage of cancer, extent of surgery, 
postoperative complications), other predictors not assessed in this study (e.g., 
number of pack years) may influence the occurrence or severity of symptoms. 
Further research is needed to identify additional predictor of symptom occurrence 
rates and/or severity ratings. 
In the third paper, a multilevel growth model was developed (111). Multilevel 
growth modelling is a complicated statistical analysis that may be unfamiliar to many 
clinicians. However, this kind of analysis has several advantages. In addition, it is 
important to use this type of analysis to the advance of the science of symptom 
management. The first advantage with this method is that it provides information 
about how demographic and clinical characteristics influence a phenomenon both 
preoperatively and over time (cross-level interaction) (111). Another advantage of 
using multilevel growth modeling is that this kind of analysis provides information on 
both the observed and the predicted values of a symptom. The observed values for 
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the individual data are the raw scores. The predicted values are the scores derived 
from the regression equation (model). When one illustrates both the predicted and 
the observed values, one can see how the predicted model fits with the observed 
values. If the observed and predicted values are similar, the model fits well with the 
observations. 
6.1.5 Reliability and validity of the study 
To insure a study’s quality, it is important to evaluate the validity and reliability 
of the instruments used in the study. An instrument’s reliability is the consistency with 
which it measures the target topic (93). In this case, it is how accurately an 
instrument measures symptom burden, comorbidity, and QOL. Reliability evaluates 
both the reproducibility as well as the internal consistency of a scale. Reproducibility 
is that repeated measurement gives the same results. Internal consistency is that all 
items in a questionnaire measure the same concept (116). As pointed out in all the 
papers in this thesis, all of the instruments used in this study were tested and found 
to be reliable (63, 90, 98-100, 105, 106). Cronbach’s alphas for MSAS are: physical 
subscale (.82), psychological subscale (.81), global distress index (.82), and total 
MSAS score (.88) (90, 117). Previous reliability testing in one study does not insure 
its reliability in a new study (93), because the questionnaires’ reliability depends on 
the patient groups that are assessed and the context of the study. However, since 
these instruments were used in a previous study of Norwegian cancer patients (98), 
even though the patients had breast cancer and were receiving different treatment, 
the results from the reliability testing seems to be transferable.  
A factor that is important for improving a study’s reliability and validity is 
representativeness. The patients in this study were recruited from three university 
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hospitals at four locations (e.g., OUS-Rikshospitalet, OUS-Ullevål, St. Olav University 
Hospital, Haukeland University Hospital), and from three of the five Regional Health 
Authorities (i.e., helseregioner) in Norway. This approach was used to increase the 
representativeness of the sample and reduce the risk of selection bias. The gender 
and age distribution in this sample were not significantly different from the total 
distribution of lung cancer surgery patients in Norway (113). A large and varied 
sample size increases the validity of a study (93). In addition, larger sample sizes 
insure a more representative sample (116). The sample (n=264) in this study was 
larger than in previous studies of symptoms and QOL in lung cancer patients prior to 
and following lung cancer surgery. In the previous studies the sample sizes range 
from 45 to 173 patients (14, 16-19).  
Validity is the degree to which an instrument measures what it is intended to 
measure and that it is useful for its intended purpose (116). Reliability and validity are 
not independent qualities of an instrument, an unreliable instrument cannot be valid 
(93).  Content validity refers to whether an instrument measures the intended topic 
(116). All three of the instruments used in this study (i.e., MSAS, EORTC QOL-LC13, 
SCQ) have established content validity (90, 100, 105).  
Other factors that are important for an instrument’s quality, especially in a 
longitudinal study, is its sensitivity (i.e., ability to distinguish between two groups) and 
responsiveness (i.e., ability of a scale to detect changes) to change (116). In this 
study, significant differences were found in symptom ratings, as well as in the scores 
for the three dyspnea items from the EORTC QOL-LC13 scale over time. Therefore, 
the instruments appear to be sensitive to change. The symptom and QOL scores 
showed changes over time, which indicates the instrument’s responsiveness to 
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changes in the patients’ experience with symptoms. Comorbidity measure was used 
at the preoperative and 5 months assessments. However, changes in comorbidity 
were not evaluated. 
Only data from the 3 item dyspnea scale from the EORTC QOL-LC13 (i.e., 
SOB at rest, SOB walking, SOB climbing stairs) were used in this thesis. This choice 
may be a limitation because it is recommended that the EORTC QOL-LC13 should 
be used with the core EORTC QOL to perform a valid assessment of a person’s QOL 
(106). However, in this thesis the scale was used to provide additional information on 
patients’ dyspnea experience. The manual for the EORTC QOL-LC13 states that the 
3 dyspnea items form a reliable scale for measuring dyspnea (106). 
6.2 General discussions
The patients in this study experienced a high number of symptoms before and 
after lung cancer surgery. The mean number of symptoms was 9 preoperatively, 13 
at one month, and 11 at five months. Previous research found that cancer patients 
experience multiple co-occurring symptoms. In a review of 18 studies of patients with 
various cancer diagnoses using multiple symptoms scales (67), 40% to 61% of 
patients experienced more than one symptom, and 22% to 30% of patients 
experienced more than five concurrent symptoms. 
This high number of symptoms affects patients’ lives in several ways. The 
occurrence of multiple symptoms is associated with decreased functional status and 
QOL (67). In addition, symptoms may slow the rehabilitation process (69). Multiple 
co-occurring symptoms may form symptom clusters. A symptom cluster is three or 
more concurrent symptoms that are related to each other (e.g., pain, fatigue, 
sleeplessness, depression) (118). The co-occurrence of several symptoms appears 
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to create a synergistic effect in that the negative effect of multiple symptoms on 
patients’ morbidity and on their QOL is greater than the simple sum of its parts (119). 
An updated literature review revealed no new research in multiple symptoms 
in patients who underwent surgery for lung cancer. Therefore, the comparison of our 
results will be done with the literature that was published at the time the manuscripts 
were written. The number of symptoms reported by patients in this study was higher 
than in previous studies of surgically treated lung cancer patients (14, 16-19). 
However, a direct comparison of the results is difficult, because the majority of the 
previous studies had a main focus on QOL and only reported a limited number of 
symptoms (16-18). In addition, different instruments were used across the studies. 
Three of the previous studies (16-18) assessed the severity of 14 symptoms using 
the EORTC QLQ-C30 and LC13, one study measured the severity of 11 symptoms 
using the Symptom Distress Scale (14), and the last study measured the severity of 6 
symptoms using the Lung Cancer Symptom Scale (19). 
One interesting finding, in the study, is that different symptoms had the highest 
occurrence rates, as well as frequency, severity, and distress ratings at five months 
after surgery (Table 4). These findings are consistent with the results of a study of 
breast cancer patients receiving CTX (63). However, they contrast with the findings 
from a study of different groups of cancer patient, that found that the symptoms with 
the highest severity and distress ratings were also the most prevalent (120). While 
both these studies used the MSAS, the reason for these differences is not evident. Of 
note, some of the symptoms that were rated as very severe or distressing in the 
present study were only experienced by a few patients, like “I don’t look like myself” 
(i.e. 13 patients) or problems with urination (i.e. 33). That different symptom is 
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experienced as distressing, severe and occurring support the need for assessing of 
multiple dimensions of symptoms. Additional research is needed to determine what 
factors contribute to patients’ perception of symptoms severity and distress.  
At five months, the majority of patients reported symptom severity scores for 
the most severe symptoms that ranged between moderate and severe. The distress 
scores for the most distressing symptoms were rated between a little bit and 
somewhat distressing. However, it should be noted that between 5% and 10% of the 
patients reported high severity distress scores. These patients warrant more 
comprehensive assessment and follow-up care Symptoms like pain, SOB, and lack 
of energy are treatable (25, 121-124). Early interventions can decrease severity and 
distress associated with these symptoms (124). 
6.2.1 Symptoms at the different assessments 
The total number of symptoms increased significantly from the preoperative (   =9.1 
SD=7.0) to the 1 month (   6' SޒDVVHVVPHQW$WPRQWKVDIWHU
surgery, the number of symptoms was lower than at 1 month but significantly higher (
 6' SޒWKDQDWWKHSUHRSHUDWLYHDVVHVVPHQW 
6.2.1.1. Preoperative symptoms
In the present study, the first data assessment were done before surgery, 
which is an advantage since a previous study reported that candidates for resection 
for lung cancer had a worse preoperative QOL compared with the general population 
(71). The most frequently reported symptoms, that were reported by more than 45% 
of the patients preoperatively, were: cough, lack of energy, feeling drowsy, SOB, 
worrying, difficulty sleeping, and dry mouth (Paper 1).  
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The most frequently reported symptoms in previous studies were: cough, pain, 
dyspnea, fatigue, and insomnia (14, 16-18). However, because the previous studies 
assessed different symptoms is it difficult to compare the results.  
The three studies that assessed symptoms using the EORTC QLQ-C30 and 
LC13 (16-18) all reported that cough and dyspnea were two of the most common 
symptoms. In addition, two of these studies reported that pain and fatigue was 
common symptoms. Why previous studies reported different symptoms is difficult to 
explain. However, all of these symptoms had high occurrence rates in our sample. 
While, the samples in two of the previous studies were quite similar to our sample 
(17, 18), the last study included only patients over 70 years (16). However, none of 
these studies reported worrying as a frequent symptom, even though the EORTC 
QLQ-C30 scale assesses this symptom. The reason for this difference is not readily 
apparent. However, it may be that the symptom was reported as a part of EORTC 
QLQ-C30 functional scales (i.e., physical, role, emotional, social and cognitive 
functioning) (18). 
 In the last study that evaluated preoperative symptom distress (14), pain, 
fatigue, and insomnia were the most distressing symptoms. Two of the three 
symptoms were the same as in our study where; “I don’t look like myself”, difficulty 
sleeping, and pain were the three most distressing symptoms.  
6.2.1.2 Symptoms at 1 month
The four symptoms with the highest occurrence rates at one month after 
surgery were SOB, lack of energy, pain, and feeling drowsy (Paper 2). SOB was the 
symptom that had the highest occurrence rate (85.5%) and its severity increased 
significantly from slight to moderate at one month. This symptom is reported to have 
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a significant impact on QOL (125) and warrants additional research. Only four studies 
have evaluated lung cancer symptoms 1 month after surgery, three with EORTC 
QLQ-C30 and LC13 (16-18), and one with Lung Cancer Symptom Scale (19). SOB, 
pain, and lack of energy were some of the most frequently reported symptoms 1 
month after surgery, in all four studies (16-19).  
The number of patients who reported pain after surgery was higher in the 
present study than in previous reports (17, 18). Pain warrants ongoing evaluation 
because higher levels of postoperative pain increase the risk for the development of 
persistent pain following thoracotomy (126). Consistent with previous studies of 
oncology patients (127) and of patients who had major surgery (128), fatigue was a 
common symptom. Feeling drowsy was a symptom frequently reported by patients in 
our study, but not measured in previous studies. The literature on this symptom is 
sparse, but in a review of symptoms in patients who underwent day surgery (129), 
feeling drowsy was reported as a frequent problem.  
Of note, both in our study and previous studies, symptoms that might affect 
patients’ nutritional status were common (i.e., lack of appetite (19), nausea (17, 18), 
vomiting (17)). More than 50% of the patients in our study reported lack of appetite at 
1 month. Surgery, as well as CTX and radiotherapy, can have a negative impact on 
patients’ nutritional status. In addition, weight loss is a poor prognostic sign in 
patients with lung cancer (130).  
6.2.1.3 Symptoms at 5 months
The six most common physical symptoms reported 5 months after surgery 
were: pain, lack of energy, feeling drowsy, difficulty sleeping, SOB, cough. The most 
frequent psychological symptom was worrying (Paper 3). These symptoms were 
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reported by more than 45% of the patients. Five previous studies assessed lung 
cancer symptoms at 4 to 6 months after surgery, three assessed symptom severity 
with EORTC QLQ-C30 and LC13 (16-18), one assessed symptom distress with 
Symptom Distress Scale (14), and one assessed symptom severity with Lung Cancer 
Symptom Scale (19). However, in these five studies the findings were inconsistent.  
In one study that assessed symptoms using EORTC QLQ-C30 and LC13 (18), 
all of the symptoms had returned to preoperative levels at 6 months after surgery. In 
another study that used the same instruments (16), all symptoms except thoracic 
pain had returned to preoperative levels after 6 months. However, in the third study 
that used the QLQ-C30 and LC13 (17), the severity of fatigue, dyspnea, and pain 
remained high at the 4 month assessment. The two studies that assessed symptoms 
using a symptom assessment scale (14, 19) found high levels of fatigue, dyspnea, 
and pain combined with a high level of cough. The reasons for these differences may 
be related to the specific symptoms that were assessed on each instrument and the 
symptom dimensions that were assessed.  
SOB was the symptom with highest occurrence rate 5 months after surgery, 
as 79% of the patients reported this symptom (Paper 3). SOB was also a frequent, 
severe, and distressing symptom.  This finding is consistent with findings from 
previous studies (17-19). SOB affects patients’ physical and social functioning. It can 
lead to clinically significant depression and to a lack of physical activity (125, 131). In 
a previous study (125), >30% of lung cancer patients reported this symptom several 
years after surgery and it had a significant negative impact on their QOL.  
One factor that may influence the occurrence and severity of SOB is smoking. 
Of note, 94% of the patients in this study were current or previous smokers. Another 
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factor that could influence SOB is pain (132, 133). In a study of COPD patients with 
dyspnea and pain (133), their two symptoms appeared to create a vicious cycle. Five 
months after surgery, 56% of the patients in the present study reported pain and 36% 
were still using analgesics’ (Paper 3). The International Association for the Study of 
Pain (IASP) defines chronic pain after thoracotomy as pain that persists for at least 3 
months after the surgical procedure (134). The finding that more than 50% of the 
patients reported pain after surgery in the present study is consistent with findings 
from previous studies (126, 135).    
Three of the 7 symptoms reported 5 months after surgery are known to be 
interrelated: namely lack of energy, difficulty sleeping, and feeling drowsy (64). Few 
studies have explored the consequences of feeling drowsy in cancer patients. 
However, both lack of energy and difficulty sleeping are often documented to 
significantly impair patients’ QOL and ability to function (127, 136). Previous studies 
in lung cancer patients have measured only lack of energy and difficulty sleeping. 
One study reported that lack of energy returned to pre-surgical levels 6 months after 
surgery (18). In the other two studies (17, 19), fatigue scores remained elevated for 
up to two years. Difficulty sleeping was reported in only one study (18), and was 
found to be a frequent problem preoperatively. 
 The severity of cough decreased over the first month then it increased from 1 
month to 5 months (Paper 3). A previous study found the same pattern for cough. 
The authors hypothesized that patients suppressed cough shortly after surgery due 
to pain (18). Regardless of the cause, cough is a distressing symptom and has 
important implications for the QOL of lung cancer patients (137, 138).  
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Worrying was the most frequent psychological symptom in the present study. 
Forty-seven percent of the patients reported this symptom at 5 months (Paper 3). A 
previous study reported that 51% of patients experienced worrying to be at least 
“somewhat of a problem” and that high levels of preoperative worry were associated 
with a significantly higher number of symptoms even before treatment (139). Patients 
in this study reported other psychological symptoms like feeling nervous (40%) and 
feeling sad (37%). The high rates of psychological symptoms as measured here may 
be related to patients’ cancer diagnosis (140). Previous studies found that 
psychological symptoms in lung cancer patients continued for up to a year and that 
these patients need psychological support (141, 142).  
Of note, 43% of the patients reported problems with sexual interest 
preoperatively and at 5 months 47% of the patients reported this symptom. Problems 
with sexual interest was the most frequent, severe, and distressing symptom at 5 
months. This symptom was not assessed in the previous studies of symptoms in 
surgically treated lung cancer patients (14, 16-19). However, in a previous study in 
lung cancer patients receiving different kind of cancer treatment (15), this symptom 
was described as severe. In a large study of causes and consequences of sexual 
changes after cancer, this symptom was described as distressing and causing 
relationship difficulties (143). Qualitative interviews with health professionals and 
patients revealed that they had different foci with regard to sexual problems (144). 
While patients wanted information, support, and practical strategies about how to live 
with intimate and sexual changes after treatment for cancer, health professionals 
focused on patients’ fertility, contraception, menopausal status, or erectile status 
(144). This finding warrants additional research to determine how clinicians assess 
sexual problems in patients with cancer (144). 
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6.2.1.4 Summary of the symptoms
The patients in this study experienced a high symptom burden over time. Both before 
and after surgery, symptoms like lack of energy and SOB had high occurrence rates, 
as well as high severity, frequency, and distress scores. However, pain was a 
symptom that increased the first month after surgery and remained quite high at five 
months. In contrast, the occurrence of cough was high at all three assessments. 
However, cough was not among the most frequent, severe, or distressing symptoms 
at five months. Psychological symptoms like worrying, feeling sad, or feeling nervous 
were common preoperatively, and their occurrence rates remained relatively high at 
one and five months after surgery. These differences suggest the need for detailed 
symptom assessments of patients before and after surgery in order to be able to 
implement effective symptom management interventions. 
6.2.2 Demographic and clinical characteristics that influence symptom burden 
Demographic and clinical characteristics had differential effects on patients’ 
symptom experiences. The analyses in Paper 2 and 3 gave different results in terms 
of which characteristics influenced patients’ symptom experience. These differences 
may be because various characteristics differ in their contributions over time. In 
paper 2, which assessed changes in symptoms from the preoperative period to one 
month after surgery, we found that the only characteristic that was associated with a 
higher number of postoperative symptoms was the number of preoperative 
symptoms reported by the patient. This finding was a bit unexpected because 
previous studies of lung cancer patients reported that demographic characteristics 
(i.e., age, gender, living situation) and clinical characteristics (i.e., preoperative FEV1, 
comorbidity, stage of cancer, extent of surgery, postoperative complications) were 
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associated with QOL and symptom scores reported 1 month after surgery (55, 86, 
125).  
However, the multilevel growth model that assessed the trajectories of 
symptoms showed that age, comorbidities, receipt of adjuvant CTX, and gender 
influenced the change in the occurrence and severity of symptoms to a different 
extent. The possible reasons for these differences are discussed under each 
demographic and clinical characteristic. 
6.2.2.1 Age
As previously mentioned, one of the initial purposes of this study was to 
evaluate symptom burden in surgically treated elderly lung cancer patients. We 
hypothesized that elderly patients would experience more symptoms than younger 
patients. In the initial analyses few age-related differences were found between older 
and younger patients. When age differences were identified, older patients reported 
lower symptom occurrence rates and lower severity and distress ratings (Paper 1 
and 3). 
Preoperatively, when 32 symptoms were assessed, older patients reported 
lower occurrence rate for feeling drowsy; a lower severity score for feeling nervous; 
and a lower distress rating for lack of energy (Paper 1). In the second paper, when 
we evaluated for changes in symptom occurrence rates and severity ratings, from the 
preoperative period to 1 month after surgery, no age-related differences were found. 
In the third paper, when we analyzed the trajectories of symptom occurrence rates 
and severity ratings from before through five months after lung cancer surgery; age 
influenced the occurrence rates for pain and feeling drowsy, and demonstrated a 
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cross level interaction (i.e., influenced the change in symptoms over time) with the 
severity of SOB when climbing stairs.  
A limited number of studies have evaluated the associations between age and 
the occurrence, severity, and distress of symptoms (117). To our knowledge, the one 
study that focused on age differences in symptoms of lung cancer patients evaluated 
symptom distress in newly diagnosed lung cancer patients (145). The study reported 
that older patients experience less symptom distress than younger patients. One 
reason why older patients report fewer symptoms may be that they are referred to 
the thoracic surgeon earlier than younger patients (140). Another explanation may be 
that older persons experience a “response shift” in symptom perceptions.  A 
“response shift” is a change in a person’s internal standard, in values, or in the 
conceptualization of experiences that are catalyzed by a change in their health status 
(146). Older patients may have experienced symptoms from other medical conditions 
for a long time which may have resulted in a reconceptualization of their symptoms 
(147). 
The results from other studies on age related differences in symptoms are 
inconsistent (117, 145, 148-150). In a study of oncology patients undergoing 
radiation therapy (RT) (149), sleep disturbance, pain, and distress were significantly 
less prevalent among older patients compared to younger patients, while SOB was 
significantly more prevalent among older patients. In another study of multiple 
symptoms in patients newly diagnosed with gastrointestinal cancer (150), patients 
>70 years of age reported higher symptom distress scores compared to patients <70 
years of age. In a study of patients with advanced cancer (148), younger patients 
reported higher pain severity scores and better appetite. In the last study of 593 
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oncology outpatients receiving active treatment for their lung cancer (117), older 
patients reported lower occurrence rates as well as lower symptom severity, 
frequency, and distress ratings. The reasons for the inconsistent findings regarding 
age-related differences in symptoms are not readily apparent. One possible 
explanation may be that different samples had different levels of comorbidity. 
6.2.2.2 Comorbid conditions and preoperative symptoms
In paper 2, the only characteristic that was associated with a higher number of 
postoperative symptoms was the number of preoperative symptoms reported by the 
patient. That the number of preoperative symptoms influenced symptom occurrence 
at 1 month is consistent with previous research (14, 18). Comorbid conditions did not 
have a significant influence on the total number of symptoms at 1 month (Paper 2). 
However, a higher level of comorbidity (i.e., higher SCQ scores) influenced the 
occurrence and severity of several symptoms when analyzed using a multilevel 
growth model (Paper 3). The reason for this difference may be that the number of 
preoperative symptoms was highly correlated with the level of comorbidity. When 
number of preoperative symptoms was removed from the general linear model, the 
SCQ scores showed a significant correlation with the number of symptoms at the 1 
month assessment. 
The SCQ score prior to surgery influenced the occurrence rates for six of the 
seven symptoms (i.e., pain, lack of energy, feeling drowsy, difficulty sleeping, SOB, 
worrying) in the multilevel growth models that analyzed changes in symptoms from 
before to five months after surgery. This finding is consistent with previous reports 
(63, 88). In the present study, no significant differences were found in the number of 
comorbid conditions between older and younger patients. The number of 
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comorbidities that patients experienced varied; 15% had no comorbidities, 23% had 
1, 26% had 2, and 37% had 3 or more comorbid conditions. The most common 
comorbid conditions were: back/neck pain (46%), hypertension (34%), and COPD 
(32%). While it is not clear which comorbid condition had the greatest influence on 
the occurrence of each symptom, the findings regarding the negative impact of 
comorbid conditions on patients’ symptom experience suggest that these patients 
warrant detailed assessments and more aggressive symptom management 
interventions.   
6.2.2.3 Gender
Gender had little impact on patients’ symptom experience in the present study. 
It did not influence the total number of symptoms 1 month after surgery. However, it 
did influence the occurrence of worrying and the severity of pain at 5 months (Paper 
3). Being female was associated with a higher symptom burden for both the 
occurrence of worrying and the severity of pain. This finding differs from a previous 
report (19) where being male was associated with a higher overall symptom severity 
score at 4 months after lung cancer surgery. Data on the influence of gender on 
oncology patients’ symptom experience are inconclusive (151). However, in two 
studies (139, 152), women reported higher occurrence rates for worrying in the 
preoperative period and higher pain intensity scores in the immediate postoperative 
period (153, 154). The reasons for these differences may be that women may have a 
lower pain threshold as well as sex-related differences in the effects of opioid 
analgesics (153). 
6.2.2.4 Adjuvant chemotherapy (CTX)
Adjuvant CTX is usually given to patients 4 to 6 weeks after surgery (44). In this 
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study, an unexpected finding was that patients who received adjuvant CTX at 1 
month had higher occurrence rates for five symptoms preoperatively. In contrast, the 
receipt of adjuvant CTX did not influence the occurrence rates for symptoms over 
time. This finding suggests that it was patients with more advanced disease who 
received adjuvant CTX. While receipt of adjuvant CTX was a significant predictor of 
symptom severity in a previous study (19), it did not influence symptom severity in 
our study (Paper 3). The association between the receipt of adjuvant CTX and an 
increased symptom burden prior to surgery is most likely explained by the fact that 
adjuvant CTX is primarily given to younger patients with more advanced disease 
(57).  
Chronological age is not a strong predictor of toxicities or responsiveness to 
CTX. In fact, many older patients tolerate CTX better than their younger counterparts 
(23). However, patient’s age is often considered when making a decision about 
adjuvant CTX. The Norwegian guidelines recommend that adjuvant CTX should not 
be given to patients >70 years of age (44). Recent studies found that patients who 
were \HDUVRIDJHEHQHILWHGIURPDGMXYDQW&7;DIWHUVXUJHU\(155, 156), and 
even patients at 75 years had the same clinical and pathological characteristics as 
younger patients (157). However, in those over 80 years of age, no additional 
survival benefit was realized (156). The presence of comorbid disease was 
prognostic in this retrospective study and may be a more relevant inclusion or 
exclusion criteria for treatment than chronologic age (84). 
6.2.3 Consequences and treatment of a high symptom burden 
The patients in this study had a high symptom burden at 5 months after 
surgery. This finding is important because the occurrence of multiple symptoms is 
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associated with decreased functional status and QOL (67) and will have a negative 
effect on patients’ rehabilitation process (69). Lung cancer patients appear to have a 
larger number of unmet psychosocial and daily living needs than other cancer 
patients (30, 158). Many patients report that life after a lung cancer diagnosis is 
difficult and that their concerns are not being met (19, 140, 159). In addition, lung 
cancer patients experience added difficulties and stigma because of the close 
connection between the disease and smoking (160-162). Patients experience stigma 
to a different degree. Of note, higher levels of lung cancer stigma (LCS) were 
associated with higher levels of anxiety and depression, as well as poorer QOL (160, 
161).  
It is important to give these patients and their family members information at 
hospital discharge about how to manage their symptoms and when to seek care for 
unrelieved symptoms (9). Close follow-up and assistance with symptom 
management are extremely important. The Norwegian guideline for diagnosis, 
treatment, and follow-up of lung cancer patients recommends that patients should be 
seen at 1 month after surgery, then every 3 months until 9 months after surgery (44). 
However, based on the high symptom burden of lung cancer patients after surgery, 
these patients may need closer follow-up and more assistance with symptom 
management either in the hospital or in an outpatient clinic.  
Cancer patients are vulnerable to an overall decrease in activity. An early 
intervention can prevent problems, as it is much easier to maintain strength and 
range of motion than to regain it (69). Rehabilitation can play a role in improving 
tolerance to treatment and adaption to disability (23). The European Respiratory 
Society (ERS) and the European Society of Thoracic Surgery (ESTS) clinical 
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guidelines on fitness for radical therapy in lung cancer patients (45) recommend early 
pre- and postoperative rehabilitation in operable lung cancer patients.  
In the present study, 42% of the patients received physical therapy and/or 
inpatient rehabilitation. When total number of symptom was compared between that 
patients’ who did and did not receive physiotherapy/rehabilitation, no differences 
were found. However, we lack knowledge about when the patients received 
physiotherapy, as well as how much and what type of physiotherapy they received. 
Both the Medical Research Council and the developers of the TSM noted that the 
intervention itself, as well as the timing and dose of the intervention are important 
considerations when evaluating an interventions effect (10, 24). A systematic review 
of exercise interventions for patients surgically treated for NSCLC concluded that 
even though the quality of the evidence has many limitations, it appears that an 
exercise intervention improved patients’ cardiopulmonary exercise capacity, 
increases their muscle strength, and reduces fatigue, post-operative complications 
and hospital length 
 of stay (122). In a recent Norwegian study (123) , high-intensity training following 
lung cancer surgery improved peak oxygen uptake, muscular strength, total muscle 
mass, functional fitness, and QOL. Until further studies are done, referrals to physical 
therapy or rehabilitation programs need to be considered for all patients who undergo 
lung cancer surgery.  
6.3 Theory of Symptom Management (TSM)
The initial purpose of this study was to develop an intervention to improve 
symptom management in surgically treated lung cancers patients. This plan was
under consideration, because in a previous, small, qualitative study done by our 
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research group, patients described a postoperative period characterized by 
discomfort and lack of support from clinicians (12). However, when a literature review 
was done; lack of knowledge about surgically treated lung cancer patients’ symptom 
experience was identified. This paucity of research made the development of a 
tailored and effective symptom management intervention difficult. The Medical 
Research Council (MRC) in United Kingdom clearly states that an intervention should 
be systematically developed based on previous evidence (24). It is also emphasized 
that if factors that caused and sustained the problem were not well understood, one 
needed to do some primary research to understand the phenomes of interest (24, 
25). 
Starting with the collection of data on patients’ symptom experience is 
consistent with how knowledge development was done in previous studies of 
symptoms in other patient groups (e.g., COPD, diabetes) (10). First studies on 
patients’ symptom experiences were done. Then symptom management 
interventions were developed and evaluated, first in terms of efficacy and then in 
terms of clinical effectiveness.   
The TSM was used as the theoretical framework for this study, because this 
theory describes how to assess symptoms and how to develop interventions to 
relieve patients’ symptom burden. The theory was useful in clarifying the 
characteristics that may influence the patients’ symptom experience (i.e. personal, 
environmental, health &illness), and how both the frequency and severity of a 
symptom influences the level of distress associated with a symptom. In addition, the 
theory explains how different types of interventions (symptom management 
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strategies) can change patients’ symptom experiences as well as associated 
outcomes (symptom outcomes). 
The main focus in this study was on the symptom experience dimension of the 
TSM. However, in addition to the data collection on patients’ symptom experience, 
we explored the relationships between symptom experience and some demographic 
and clinical characteristics in the three domains of nursing science (i.e., person, 
environment, health & illness). Data were collected on how age and gender from the 
person domain affects patients’ symptom experience. In addition, we evaluated how 
comorbidity, receipt of adjuvant CTX, and number of preoperative symptoms from the 
health & illness domain affected patients’ symptom experience.  We also collected 
some information on symptom management strategies (i.e. rehabilitation, 
physiotherapy) and symptom status outcome (i.e. patients employment status, SOB 
at rest, SOB when walking, SOB climbing stair) symptom.  
In this study, we collected data about which symptoms had the highest 
occurrence rates as well as which symptom were the most severe, distressing, and 
frequent at different assessment points. This information is a good starting point to 
develop and test an intervention to relive symptoms in surgically treated lung cancer 
patients. The next step in our research group will be to develop and test symptom 
management interventions to ease patients’ symptom status; either by making the 
symptom less frequent, less intense, or less distressing. The best way to develop 
and test interventions is by starting with a series of pilot studies, and moving on to 
exploratory studies and then to a definitive evaluation (24). This approach is called a 
pragmatic design (163). When these pilot testes are done, it is possible to design and 
conduct a randomized controlled trial; where on group of patients receives the 
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intervention and the other group receives either standard care or some type of 
alternative  
control intervention. Then the effects of the intervention on patients’ symptoms could 
be evaluated. 
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7.0 CONCLUSIONS AND CLINICAL IMPLICATIONS 
This dissertation provides evidence that surgically treated lung cancer patients 
experience a high symptom burden. At 5 months, the number of symptoms was 
significantly higher than at the preoperative assessment. This high symptom burden 
in lung cancer patients before and after surgery requires that clinicians perform a 
comprehensive symptom assessment prior to surgery and at regular intervals after 
surgery. Psychological symptoms (e.g., worrying) were common, especially 
preoperatively, and warrant consideration because of their negative effects on 
postoperative outcomes (164). It is important that clinicians speak with patients about 
their concerns and initiate referrals to mental health professionals if warranted. 
The findings from this study can be used to identify patients who are at higher 
risk for more severe symptoms before and after lung cancer surgery and to initiate 
more aggressive symptom management interventions. Patients with comorbidities 
and a higher number of preoperative symptoms need special attention because they 
tend to experience a higher number of postoperative symptoms.  
The results in this study can be used to improve the information given to the 
patients about the normal course of postoperative recovery after lung surgery. More 
knowledge about which symptoms are expected after lung cancer surgery and how 
to cope with these symptoms can make the rehabilitation period easier for the 
patients. Even though it is recommended (45), less than 50% of the patients in this 
study received physical therapy or inpatient rehabilitation. The number of patients 
who worked decreased from 30% preoperatively to 9% at five months after surgery.  
 In summary, this clinical, interdisciplinary multi-center, study with 264 lung 
cancer patients provides important information on the symptom burden of these 
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patients who underwent lung cancer surgery. This information can be used to 
develop tailored symptom management interventions and that may significantly 
improve postoperative and survivorship outcome for this group for this group of 
patients.  
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8.0 FUTURE RESEARCH
Additional studies are needed to confirm the findings from this study. For 
example, future studies could evaluate if patient who undergo different types of 
surgical procedures (e.g., thoracotomy or VATS) have different symptom 
experiences. It would be interesting to see if other studies find similar patterns as in 
this study, namely that younger lung cancer patients experience a higher symptom 
burden than older patients. Future studies could evaluate for subgroups of patients 
which experience higher symptom burden, using statistical approaches like latent 
class analyses (165, 166). In addition, future studies could evaluate for the number 
and types of symptom cluster in these patients and whether the number and types of 
symptom cluster change over time. Additional research needs to focus on the 
etiology of the symptoms identified. In addition, it is important to develop and test 
symptom management interventions to improve symptom management in these 
patients. It is important that these interventions focus on multiple symptoms and that 
they help patients to cope with their symptom burden. 
Future studies could focus on additional elements of the TSM. For example, 
studies could focus on the impact of symptom management strategies on the 
patients’ symptom experience. Then it would be possible to evaluate how this 
intervention influences symptom outcomes. This change in symptom status can 
either be that the symptom is less frequent, less intense, or less distressing, or 
remains the same. The assessment should be longitudinal as symptom burden 
varies over time. In addition, one could evaluate whether changes in symptom status 
has an impact on a variety of symptom outcomes (e.g., QOL, return to work)  
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2010 Lungeoperasjonsstudien
Rehabilitering etter lungeoperasjon
Pasientens navn: ____________________________________________
2010 Lungeoperasjonsstudien
2010 Lungeoperasjonsstudien Reg.nr  
CRF 1    Inklusjon
Sykehus:  OUS - Rikshospitalet  OUS - Ullevål  St. Olav  Haukeland
Skriv tydelig med store bokstaver (evt lim:
Fornavn :…………………………………………………………………………………
Etternavn : ………………………………………………………………………………...
Adresse : ………………………………………………………………………………...
Postnr : ..................... Sted: …………………………………………………
Telefonnummer: 
Fødselsdato:           
dag måned år
Kjønn:     Mann  Kvinne
              
Inklusjonskriterier
1. Menn og kvinner over 18 år  Ja  Nei
2. Mistanke om lungekreft   Ja  Nei
3. Ingen kognitive forstyrrelser  Ja  Nei
4. Kunne lese og skrive norsk  Ja  Nei
Kontrollert: 
Informert samtykke mottatt  Ja  Nei
Spørreskjema mottatt  Ja  Nei
Registrering nr. mottatt  Ja  Nei
Fyll ut skjema, send melding til Trine på tlf: 91774995 for tildeling 
av registreringsnummer. Skriv dette øverst i høyre hjørne (også på 
spørreskjema). Samle alle skjemaene i en konvolutt og oppbevar på 
avtalt sted.
       ……………………………………
dag måned år signatur
2010 Lungeoperasjonsstudien
CRF 2
Røyking :  Ja  Nei ,ikke lenger  Nei
Fra år:  Til år:           
Ca antall sigaretter pr dag (en sigarett tilsvarer ca 1 gram tobakk): 
Hvordan ble sykdommen oppdaget:
1. Pasienten hadde symptomer    Ja  Nei
2. Røntgen thorax tatt i utredning av annen sykdom       Ja  Nei
3. Screening  Ja  Nei
Kliniske funn og undersøkelser preoperativt:
Høyde:  cm
Vekt:  kg
FEV1: ,  liter
FVC: ,  liter
Medisiner preoperativt:
 Psykofarmaka Hvilke……………………………………..
 Smertestillende medikament: Hvilke……………………………………..
   Steroid inhalasjon (Pulmicort/ Flutide)
 Beta-2-agonist inhalasjon (Ventoline/ Bricanyl/ Oxis/ Serevent)
   Anticholinergica inhalasjon (Spiriva/ Atrovent /Ipraxa)
 Kombipreparat inhalasjon (Symbicort/ Seretid)
   Steroid tabletter (Prednisolon)
Tumortype:
 Adenokarsinom
 Plateepitelkarsinom
   Storcellet
 Ikke småcellet
 Annet…………………………………………
2010 Lungeoperasjonsstudien
TNM klassifikasjon (fra patolog):
T: 
N: 
M: 
Operasjonsdag: . . 
Operasjonstype:
 Lobektomi
 Bilobektomi
   Pneumonektomi (pulmektomi)
 Kilereseksjon/ Wedge
 Annet: …………………………………………
 
Postoperativt:
Antall døgn med dren:    dager
Antibiotika skiftet:  Ja  Nei
Reoperajon:  Ja  Nei
CRP først fallt, deretter steget:  Ja  Nei
Andre komplikasjoner: …………………………………………
 
 
 
 
Pasienten overflyttet til annet sykehus postoperativt:  Ja  Nei
Sykehus pasienten ble overflyttet til: ................................................................
Appendix 2 
Inklusjon 
Inklusjon: Nå dere skal inkludere pasienten finner dere først fram inklusjonsmappe. Ta med 
”informert samtykke” forteller deretter pasienten litt om studien. Det er viktig å sjekke om pasienten 
har hørt at det er mistanke om kreft før du gir pasienten arket med ”Informert samtykke”. Dersom 
pasienten ikke vil være med i studien noteres dette på ark. Det skal noteres kjønn, alder og evt. årsak 
– dersom pasienten oppgir dette. Dersom pasienten ikke oppgir årsak skal dere ikke spørre om dette.  
Dersom pasienten vil være med i studien skal han og du underskrive på ”Informert samtykke”. Der 
det står rolle i studien skal dere skrive prosjektmedarbeider. Etter dere begge har underskrevet tas 
kopi av informert samtykke og levere dette til pasienten sammen med spørreskjema. Det er viktig å 
gjøre pasienten oppmerksom på at på side 9 i spørreskjema (der en spør om smerte)- at dersom 
vedkommende ikke har smerter så skal han hoppe til side 12 i skjema.  Sykepleier må nå fylle ut 
første side i CRF skjema (CRF 1). Det kan enten skrive for hånd eller ta en merkelapp med 
pasientopplysninger. Etterpå sender sykepleier en tekstmelding eller ringe til meg for å få 
inklusjonsnummer og skrive dette på alle dokumentene.  Skriv opp hva dere har gjort på inklusjons 
sjekklisten.  
Dersom dere lurer på noe må dere gjerne ringe meg enten på telefon nummer: 91774995 eller mobil 
91173965. 
Samtale ved inklusjon (Viktig å finne et sted som man kan være i fred, jeg sitter meg alltid 
ned). Bør bare ta med samtykket når du går inn første gangen og ikke de andre papirene. 
Hei mitt navn ……. Årsaken til at jeg kommer og snakker med deg nå er at vi holder på med 
en studie (på avdelingen/ sykehuset). Bakgrunnen for studien er at vi vet lite om hvordan 
pasienter som blir operert i lungene har det etter operasjonen. Dette gjør det vanskelig å 
forberede pasientene på hva som venter etter operasjonen. Dersom det er noe mange er 
plaget med kan vi kanskje gjøre noe for å forebygge dette. 
For å finne ut mer om hvordan pasientene har det har vi startet opp en studie som vi nå ber 
deg om å delta i. Studien innebærer for deg at du må svare på noen spørreskjema i tiden 
etter operasjonen. For å finne ut hvilke plager som du har hatt lenge og hvilke som evt. 
kommer etter operasjonen må du fylle ut første spørreskjema før operasjonen. Du trenger 
ikke gjøre det med en gang, men må gjøre det i løp av dagen. Her er litt informasjon om 
studien (levere samtykket) som du kan lese før du bestemmer deg for om du vil delta. 
Deltagelse i studien er frivillig og du vil få samme behandling selv om du ikke deltar. 
Til slutt: Takk for hjelpen og lykke til med operasjonen. 
Vanlige spørsmål:  
- Tidsbruk til utfylling av spørreskjema? Dette er ca ½ time, varierer litt fra pasient til 
pasient. 
- Hvor mange spørreskjema må besvares? Til sammen 5, ett før operasjon. Deretter 
etter 1,5,9 og 12 måneder. Grunnen til mellomrommet mellom 1 og 5 måneder er at 
en del pasienter får cellegift da. 
- Hva skal spørreskjema brukes til? Resultatene vil bli publisert i nasjonale og 
internasjonale tidsskrift. Det er en sykepleier som skal ta doktorgrad på resultatene 
(noen pasienter synes det er veldig spennende) 
- Hvem er med i studien? Oslo Universitetssykehus – Rikshospitalet og Ullevål og St 
Olavs hospital er med i studien. Studien er finansiert av kreftforeningen. 
Forespørsel om deltakelse i forskningsprosjektet 
 ”Rehabilitering etter lungeoperasjon” 
Bakgrunn og hensikt 
Dette er en forespørsel til deg som skal opereres med mistanke om lungekreft, om å delta i en studie 
for å få mer kunnskap om hvordan du opplever det første året etter operasjon. Studien vil kartlegge 
hvilke symptomer og plager pasienten kan oppleve, hvordan symptomer opptrer sammen og hvordan 
symptomene forandrer seg over tid. Studien vil også kartlegge hvilken støtte pasienten får etter 
operasjonen. Ved å få mer kunnskap om dette håper vi å kunne tilby bedre støtte og behandling til 
pasienter etter lungekreftoperasjon. Studien gjennomføres av Senter for Pasientmedvirkning og 
Sykepleieforskning ved Oslo Universitetssykehus, i samarbeid med Hjerte-, lunge og karklinikken ved 
OUS, Lungeavdelingen ved Haukeland Universitetssykehus samt Thoraxkirurgisk avdeling ved St 
Olavs Hospital.
Hva innebærer studien? 
Alle som deltar i studien vil bli bedt om å fylle ut spørreskjema for å kartlegge ulike symptomer som 
smerte, tung pust, hoste tretthet (fatigue), søvnforstyrrelser, ernæringsproblemer, livskvalitet, angst og 
depresjon. Du vil også bli spurt om evt. andre sykdommer, helsetilstand, funksjonsstatus og hvilken 
sosial støtte du har fått etter operasjonen. For å kartlegge evt. endringer av symptomer over tid ønsker 
vi å følge deg i et år. Dette innbærer at du først fyller ut spørreskjema rett før operasjonen, deretter vil 
du få tilsendt skjema etter en, fem, ni og tolv måneder. Vi vil evt. ringe deg og minne deg på utfylling 
av skjemaene. Dersom du trenger hjelp til utfylling av skjema vil undertegnede være tilgjengelig på 
telefon. Det vil ta i underkant av en time og fylle ut spørreskjemaene. 
Noen av de som samtykker i å delta studien vil bli forespurt om å bli intervjuet muntlig om hvordan de 
opplevde det å bli overflyttet til lokalsykehus og om hvordan det har vært og komme hjem. Intervjuene 
vil enten bli gjort hjemme hos deg eller hvis du ønsker det på et sykehus i nærheten av der du bor. 
Intervjuene vil bli tatt opp på bånd og deretter bli skrevet ut. Det er fult mulig å si nei til deltagelse i 
denne delen av prosjektet selv om du deltar i resten av studien. 
Mulige fordeler og ulemper 
Studien medfører ingen kostnader og det er ingen risiko forbundet med studien. Du vil kanskje 
oppleve det som slitsomt eller belastende å svare på noen av spørsmålene i spørreskjemaet. Vi vil bistå 
deg med hjelp til utfylling av skjemaer dersom du ønsker det, og du kan bruke så lang tid du ønsker på 
utfyllingen.
Hva skjer med informasjonen om deg?
Informasjonen som registreres om deg skal kun brukes slik som beskrevet i hensikten med studien. 
Alle opplysningene vil bli behandlet uten navn og fødselsnummer eller andre direkte gjenkjennende 
opplysninger. Evt. lydbånd som er tatt opp vil bli slettet etter intervjuet er skrevet ut. En kode, som vil 
være unik for hver deltager i studien, vil knytte deltagerne til opplysninger. Listen som sammenkobler 
koden og personnummer, oppbevares innelåst i et skap, fysisk atskilt fra svarene på spørreskjemaene. 
Det er kun autorisert personell knyttet til prosjektet som har adgang til navnelisten og som kan finne 
tilbake til deg. Vi regner med at studien i si helhet vil avsluttes i 2014, og at listen med koder vil 
slettes senest 5 år etter studien er avsluttet.
Som en del av studien ønsker vi informasjon om din sykdom, tilleggssykdommer og medisiner du står 
på fra din journal på sykehuset. Du vil ha rett til å ha innsyn i hvilke opplysninger som er registrert, 
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samt til å kreve retting av feilaktige opplysninger. Vi ønsker også å registrere opplysninger om alder, 
kjønn, diagnose og operasjonstype på dersom du sier nei til å delta i studien. 
Oslo Universitetssykehus ved administrerende direktør er dataansvarlig for studien. Studien er 
godkjent av Regional Etisk Komité Sør-Øst Norge og Personvernombudet ved Oslo 
Universitetssykehus, avdeling Rikshospitalet. Det vil ikke være mulig å identifisere deg i resultatene 
av studien når disse publiseres 
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke 
til å delta i studien uten at dette vil få konsekvenser for din videre behandling. Dersom du ønsker å 
delta, undertegner du samtykkeerklæringen på siste side. Om du nå sier ja til å delta, kan du senere 
trekke tilbake ditt samtykke uten at det påvirker din øvrige behandling. Du kan kreve at innsamlet data 
blir slettet. Data som allerede er analysert og publisert kan ikke trekkes tilbake.
Dersom du senere ønsker å trekke deg eller har spørsmål til studien, kan du kontakte sykepleier og 
doktorgradsstipendiat Trine Oksholm (trine.oksholm@rr-research.no, tlf: 23075437, eller mobil: 
91173965), eller prosjektleder Tone Rustøen (tone.rustoen@rr-research.no, tlf: 23075462). 
Med vennlig hilsen 
      Tone Rustøen  Johny Kongerud Trine Oksholm 
(sykepleier og professor) (seksjonsoverlege og forsker) (sykepleier og stipendiat) 
Samtykke til deltakelse i studien
Jeg er villig til å delta i studien  
---------------------------------------------------------------------------------------------------------------- 
(Signert av prosjektdeltaker, dato) 
Jeg bekrefter å ha gitt informasjon om studien 
---------------------------------------------------------------------------------------------------------------- 
(Signert, rolle i studien, dato) 
Registreringsnummer

Baseline  Registreringsnummer
Lungeopererte
”Vi vil vite hvordan du har det” 
Spørreskjema til deltagere i studien 
Dette er første spørreskjema til deg som har samtykket i å delta studien i studien. Du 
kan oppleve at noen av spørsmålene overlapper hverandre. Grunnen til dette er at vi 
bruker standardiserte skjemaer som gjør det mulig å sammenligne resultatene fra 
denne studien med andre studier. Vi ber deg svare på alle spørsmålene selv om du 
synes noen av dem ikke passer helt til deg. 
Mange takk 
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SYMPTOMLISTE (MSAS)
Veiledning:  Vi har listet opp 32 symptomer nedenfor.  Les hvert av dem nøye.  Hvis du har hatt symptomet i løpet av
siste uken, la oss få vite hvor ofte du hadde det, hvor kraftig det var det meste av tiden, og hvor mye det plaget eller
bekymret deg, ved å sette ett kryss i den ruten du synes passer best.  Hvis du IKKE HAR HATT symptomet, sett ett
kryss i den ruten merket HAR IKKE HATT symptomet.
     Reg. nr.:
Vanskelig å konsentrere seg
Smerter
Har lite energi
Hoste
Føler meg nervøs
Tørr i munnen
Kvalme
Søvnig, mye trøtt
Nummen / prikker i hender / føtter
Søvnvansker
Luft i magen / oppblåst
Problemer med vannlating
Kaster opp
Kortpustet
Diaré
Føler meg trist
Svette
Bekymrer meg
Problemer med seksuallyst /
aktivitet
I løpet av den
siste uken:
Har du hatt noen
av de følgende
symptomene?
      Hvis JA:
Hvor ofte hadde
du symptomet?
      Hvis JA:
Hvor kraftig var
symptomet, det
meste av tiden?
     Hvis JA:
Hvor mye plaget
eller bekymret
symptomet deg?
Svæ
rt mye 
Ganske mye 
En del 
Litt 
Ikke i det 
hele tatt 
Svæ
rt  
kraftig 
Kraftig 
Moderat 
Svakt 
Nesten  
hele tiden 
Ofte 
Av og til 
Sjelden 
H
ar ikke hatt sym
ptom
et
1 / 2XX Studien Kontor for klinisk forskning, Rikshospitalet HF
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SYMPTOMLISTE (MSAS) - del 2
Kløe
Manglende matlyst
Svimmel / ør
Vanskelig å svelge
Føler meg irritabel
Sår i munnen
Maten smaker annerledes
Vekttap
Mistet håret
Treg mage / forstoppelse
Hoven i armer og ben
"Jeg ser ikke ut som meg
 selv lengre"
Forandringer i huden
I løpet av den
siste uken:
Har du hatt noen
av de følgende
symptomene?
      Hvis JA:
Hvor ofte hadde
du symptomet?
      Hvis JA:
Hvor kraftig var
symptomet, det
meste av tiden?
     Hvis JA:
Hvor mye plaget
eller bekymret
symptomet deg?
Svæ
rt mye 
Ganske mye 
En del 
Litt 
Ikke i det 
hele tatt 
Svæ
rt  
kraftig 
Kraftig 
Moderat 
Svakt 
Nesten  
hele tiden 
Ofte 
Av og til 
Sjelden 
H
ar ikke hatt sym
ptom
et 
Hvis du har hatt noen andre symptomer i løpet av den siste uken,
vennligst skriv de opp nedenfor, og angi hvor mye det
plaget eller bekymret deg.
Annet:
Annet:
Annet:
Svæ
rt mye 
Ganske mye 
En del 
Litt 
Ikke i det 
hele tatt 
     Reg. nr.:
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Livskvalitetsskjema (EORTC)
Vi er interessert i forhold vedrørende deg og din helse.  Vær vennlig å besvare hvert spørsmål ved  å
sette et kryss x i den boksen som best beskriver din tilstand.  Det er ingen "riktige" eller "gale" svar.
1.  Har du vanskeligheter med å utføre anstrengende aktiviteter,
 slik som å bære en tung handlekurv eller en koffert?
2.  Har du vanskeligheter med å gå en lang tur?
3.  Har du vanskeligheter med å gå en kort tur utendørs?
4.  Er du nødt til å ligge til sengs eller sitte i en stol
 i løpet av dagen?
5.  Trenger du hjelp til å spise, kle på deg, vaske deg
 eller gå på toalettet?
I løpet av den siste uka:
6.  Har du hatt redusert evne til å arbeide eller utføre
 andre daglige aktiviteter?
7.  Har du hatt redusert evne til å utføre dine hobbyer
 eller andre fritidsaktiviteter?
8.  Har du vært tung i pusten?
9.  Har du hatt smerter?
10.    Har du hatt behov for å hvile?
11.   Har du hatt søvnproblemer?
12.    Har du følt deg slapp?
13.    Har du hatt dårlig matlyst?
14.    Har du vært kvalm?
Ikke  i det
hele tatt Litt En del
Svært
mye
Ikke  i det
hele tatt Litt En del
Svært
mye
Draft
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15.    Har du kastet opp?
16.    Har du hatt treg mage?
17.    Har du hatt løs mage?
18.    Har du følt deg trett?
19.    Har smerter påvirket dine daglige aktiviteter?
20.    Har du hatt problemer med å konsentrere deg,
   f.eks. med å lese en avis eller se på TV?
21.    Har du følt deg anspent?
22.    Har du vært engstelig?
23.    Har du følt deg irritabel?
24.    Har du følt deg deprimert?
25.    Har du hatt problemer med å huske ting?
26.    Har din fysiske tilstand eller medisinske behandling
   påvirket ditt familieliv?
27.    Har din fysiske tilstand eller medisinske behandling
   påvirket dine sosiale aktiviteter?
28.    Har din fysiske tilstand eller medisinske behandling
   gitt deg økonomiske problemer?
Som svar på de neste spørsmålene, sett et kryss i den ruten som best beskriver din tilstand.
29.    Hvordan har din helse vært i løpet av den siste uka?
30.    Hvordan har livskvaliteten din vært i løpet av den siste uka?
 1  2  3  4  5  6  7
Helt
utmerket
Svært
dårlig
Ikke  i det
hele tatt Litt En del
Svært
myeI løpet av den siste uka:
 1  2  3  4  5  6  7
Helt
utmerket
Svært
dårlig
Draft
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NORWEGIAN
 
EORTC QLQ - LC13
Endel pasienter opplever av og til at har noen av følgende symptomer eller problemer. Vær
vennlig å angi i hvilken grad du har hatt disse symptomene eller problemene i løpet av den siste
uka. Sett en ring rundt det tallet som best beskriver din tilstand.
____________________________________________________________________________________
I løpet av den siste uka: Ikke I det Svært
hele tatt Litt Endel mye
31. Hvor mye har du hostet ? 1 2 3 4
32. Har du hostet blod ? 1 2 3 4
33. Har du vært tungpustet i hvile ? 1 2 3 4
34. Har du vært tungpustet når du har gått ? 1 2 3 4
35. Har du vært tungpustet når du har gått i trapper ? 1 2 3 4
36. Har du vært sår i munnen eller på tungen ? 1 2 3 4
37. Har du hatt svelgproblemer ? 1 2 3 4
38. Har du hatt prikkinget (stikninger) i hendene eller i bena ? 1 2 3 4
39. Har du hatt håravfall ? 1 2 3 4
40. Har du hatt smerter i brystet ? 1 2 3 4
41. Har du hatt smerter i arm eller skulder ? 1 2 3 4
42. Har du hatt smerter i andre deler av kroppen ? 1 2 3 4
Hvis ja, hvor har du hatt vondt ? ______________________
43. Har du brukt smertestillende medisiner ?
1. Nei 2. Ja
Hvis Ja, hvor mye har det hjulpet ? 1 2 3 4
© QLQ-C30-LC13 Copyright 1994 EORTC Study Group on Quality of life. All rights reserved
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TILLEGGSSYKDOMMER (SCQ-18)
Det følgende er en liste over vanlige medisinske problemer. Sett ett kryss for hvert
problem om hvorvidt du har problemet nå (ja eller nei).
Hvis du HAR problemet, så svar på spørsmålene om behandling og aktiviteter til høyre.
Hvis du IKKE HAR problemet, gå videre til neste problem.
1.   Hjertesykdom
2.   Høyt blodtrykk
3.   Andre lungesykd. (KOLS)
4.   Diabetes
5.   Magesår/magesykdom
6.   Tarmsykdom
7.   Nyresykdom
8.   Leversykdom
9.   Anemi eller annen blodsykdom
10.  Hodepine
11.  Depresjon
12.  Slitasjegikt/artrose
13.  Rygg/nakkesmerter
14.  Leddgikt/revmatoid artritt
15.  Sykdom i bindevev eller muskulatur
16.  Hudlidelser
17.  Andre medisinske problemer (angi)
   Har du
problemet?
HVIS JA:
Får du behandling
       for det?
      HVIS JA:
  Begrenser det
dine aktiviteter?
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Draft
Lungeoperasjon studien 15 

Rehabilitering etter lungeoperasjon 
Kjære deltager i studien 
Nå har det gått 1 måned siden du ble med i denne studien og fylte ut spørreskjema på 
sykehuset før lungeoperasjonen. Hensikten med studien er å få mer kunnskap om hvordan 
pasientene har det i tiden etter de operert. Som avtalt sender vi deg nå spørreskjema til 
utfylling samt en frankert konvolutt som du kan bruke til å sende skjemaene tilbake til oss. Vi 
håper du kan fylle det ut så snart som mulig. Dersom du glemmer å sende skjema tilbake vil 
vi sende et deg et påminningsbrev om et par uker. Deltagelse i studien er frivillig. 
Dersom du har spørsmål om selve studien eller det er noe uklart med spørsmålene kan du 
ringe sykepleier og stipendiat Trine Oksholm ved Senter for pasientmedvirkning og 
sykepleieforskning på mobiltelefon: 917 74 995 eller eventuelt e-post:
trine.oksholm@oslo-universitetssykehus.no.
Med vennlig hilsen 
      Tone Rustøen         Johny Kongerud       Trine Oksholm 
(sykepleier og professor) (seksjonsoverlege og forsker) (sykepleier og stipendiat) 
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